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The Association Of Patients' Analgesic Treatment Beliefs And Trade-Offs With
Analgesic Adherence Behaviors Among Outpatients With Cancer Pain
Abstract
Pain is one of the most burdensome symptoms for patients with cancer. Per cancer pain guidelines,
opioids remain one of the primary modalities for managing moderate to severe cancer pain. Analgesic
nonadherence is common among cancer patients despite unmanaged pain symptoms. We investigated
how patients prioritized analgesic treatment beliefs for cancer pain and whether those beliefs predicted
objective analgesic adherence behaviors.
This is a secondary analysis of an existing dataset (n=207) that used a three-month prospective
observational design. Subjects were from outpatient oncology clinics of a large Philadelphia health
system and were > 18 years, self-identified as African-American or White, diagnosed with solid tumor or
multiple myeloma, and prescribed at least one around-the-clock analgesic for reported cancer pain.
We conducted three studies to achieve the aims. First, we performed a concept analysis (Chapter 2) of
analgesic nonadherence for cancer pain and qualified its utility in the context of the United States opioid
epidemic. In Chapter 3, we used maximum difference scaling to identify how patients traded-off on
analgesic treatment beliefs. Utilities (importance scores) were ranked using a k means cluster analysis;
clusters were compared in terms of key variables. Finally, we employed general linear modeling to
evaluate if analgesic belief clusters predicted analgesic adherence behaviors, assessed longitudinally
using electronic medication monitoring while accounting for relevant confounders (Chapter 4).
Initial results showed beliefs weigh significantly in subjective analgesic trade-offs. We identified two
distinct belief clusters. Side effect severity was the only variable that significantly differed between
clusters. Subjects mostly traded-off based on the belief, ‘pain medicines keep you from knowing what is
going on in your body.’ Addiction was not a top priority. Belief clusters did not predict analgesic
adherence. However, in an adjusted analysis, it was the experiential variables (e.g., side effects, most
potent analgesia, pain relief with analgesics, duration of disease), as well as patients’ race, that were
statistically significant in explaining analgesic adherence.
Our findings suggest that experiential variables rather than analgesic beliefs were associated with
analgesic adherence in this sample of cancer outpatients. Additional studies should explore patients’
cancer pain self-management practices while considering patient, provider, and system/ structural factors
to optimizing cancer pain management.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Nursing

First Advisor
Salimah H. Meghani

Keywords
analgesic adherence, analgesic beliefs, cancer pain, opioid crisis, opioid epidemic, pain management

Subject Categories
Medicine and Health Sciences | Nursing | Oncology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3790

THE ASSOCIATION OF PATIENTS’ ANALGESIC TREATMENT BELIEFS
AND TRADE-OFFS WITH ANALGESIC ADHERENCE BEHAVIORS
AMONG OUTPATIENTS WITH CANCER PAIN
William E. Rosa
A DISSERTATION
in
Nursing
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2020
Supervisor of Dissertation
________________________
Salimah H. Meghani, PhD, MBE, RN, FAAN
Associate Professor of Nursing, University of Pennsylvania School of Nursing
Graduate Group Chairperson
_________________________
Nancy A. Hodgson, PhD, RN, FAAN
Associate Professor of Nursing, University of Pennsylvania School of Nursing
Dissertation Committee
Connie M. Ulrich, PhD, RN, FAAN

Professor of Nursing

Barbara Riegel, PhD, RN, FAAN, FAHA

Professor of Nursing

THE ASSOCIATION OF PATIENTS’ ANALGESIC TREATMENT BELIEFS
AND TRADE-OFFS WITH ANALGESIC ADHERENCE BEHAVIORS
AMONG OUTPATIENTS WITH CANCER PAIN
COPYRIGHT
2020
William E. Rosa

DEDICATION
For the patients, families, and communities I have been so privileged to care for
and
for my palliative care colleagues working to alleviate
serious health-related suffering worldwide.

iii

ACKNOWLEDGMENT

Words fall short in expressing the overwhelming extent of gratitude I have for the
inspirational, expert faculty at the University of Pennsylvania, scholarly mentors, clinical
and academic colleagues, professional organizations, my spiritual and healing
communities and - my very foundation of love and support – my incredible friends and
family. I am a blessed and fortunate man.
I would like to start by pausing to acknowledge and humbly express gratitude to
every patient, family member, and community I have had the deep honor of caring for
over my ten years in nursing. From critical to palliative care settings, from New York to
Africa, during the early morning hours of night shift and the hurried tasks of the day, I
carry each one of you in my mind and heart. You have informed my life, my work, and
my life’s work in unimaginable ways and to an incomprehensible extent. It is in the quiet
moments we have shared, the things you have taught me about living and dying, and the
bold courage you have demonstrated amid your suffering that I have developed my sense
of compassion and love for humanity. You are my reason for being of service in the
world. Ralph Waldo Emerson wrote, “To know even one life has breathed easier because
you have lived. This is to have succeeded.” My prayer is I have done this for you in some
small way in the past and will have the privilege of continuing to serve you in the future.
I would like to give wholehearted thanks to my dissertation chair, Dr. Salimah H.
Meghani. She has demonstrated exemplary leadership, mentorship, and methodological
expertise throughout my doctoral studies. Dr. Meghani has shown me tremendous
iv

patience, kindness, and understanding, particularly at times of uncertainty for which I
cannot thank her enough. Of importance, she has instilled in me a passion for research
that will inform my professional development throughout my career.
Dr. Connie M. Ulrich has offered critical contributions throughout the dissertation
process as a committee member, providing ethical and pragmatic input that has informed
my growth as a scientist and scholar. I am deeply grateful for her consistent academic
excellence and reliable encouragement to consistently improve the quality of this work.
Dr. Barbara Riegel has been influential as both a teacher and committee member,
role modeling collaborative team science and mastery of scholarly writing. She has
offered endless insights to optimize the planning, development, and execution of this
dissertation and has been a wealth of professional support throughout the PhD program.
I cannot thank Jesse Chittams enough for his statistical guidance and
encouragement. I entered the program with significant insecurity about quantitative
methods (p < 0.001) and, over time, Jesse truly helped me to develop confidence and to
think critically and autonomously about analytical approaches. He has opened up new
possibilities for me as a researcher through his supportive teaching methods.
I am so very grateful to Drs. Peggy Compton, Dalmacio Dennis Flores, and
Adriana Perez for serving as readers for my candidacy exam and/or my dissertation. In
addition, thank you to Ryan Quinn and Zeyu “Max” Miao for additional statistical
assistance throughout the empirical portions of the study. My appreciation to Allison

v

Schlak for her incredibly generous data visualization expertise in preparation of my
dissertation defense. This group’s collective time, energy, and input has been invaluable.
Deep thanks to all the faculty at the University of Pennsylvania School of Nursing
and the Department of Medical Ethics and Health Policy who have been a part of my
scholarly and professional development over the past three years - both inside and outside
of the classroom. Much gratitude to our librarians, especially Richard James and Sherry
Morgan - database wizards who seamlessly weave together technical savvy with genuine
kindness. Gracious acknowledgment to the entire student and graduate academic affairs
staff at Penn Nursing who have co-created a wonderful PhD student experience and
always responded to questions with patience and generosity, especially Janae Lamoureux
and Antoinette Oteri.
Additional mentors have been a constant source of strength and support in
countless ways. I am eternally grateful to Dr. Betty Ferrell (City of Hope, Duarte, CA).
She has never failed to be fully present during both times of challenge and celebration.
Without Dr. Ferrell’s words of wisdom, authenticity, and last-minute phone calls I am not
sure I would have made it through this journey. Dr. Suzanne Miyamoto (American
Academy of Nursing, Washington, D.C.), has been both mentor and friend, providing
endless encouragement that has expanded my professional aspirations and career goals in
alignment with my personal values. Drs. Terry Fulmer (The John A. Hartford
Foundation, New York, NY) and Barbara Dossey (International Nurse Coach
Association, North Miami, FL), have been exemplary mentors and friends in leadership,
scholarship, and advocacy, also serving as my fellowship sponsors to the American
vi

Academy of Nursing. Drs. Eileen Breslin (University of Texas Health Science Center San
Antonio School of Nursing, San Antonio, TX) and Anne Teitelman (University of
Pennsylvania School of Nursing, Philadelphia, PA) have provided ongoing professional
encouragement as valued mentors and my fellowship nominators to the American
Association of Nurse Practitioners.
A number of academic colleagues – who have become dear friends – have
partnered with, taught, supported, believed in, and loved me throughout my doctoral
program in deeply humbling ways for which I will be forever in awe. A deep bow of
gratitude and respect (in no particular order) to Michele Upvall, Jean Watson, Allison
Squires, Wendy Budin, Marilyn Ray, Mary Jo Kreitzer, Mary Koithan, Deva-Marie
Beck, Donatilla Mukamana, Phalakshi Manjrekar, Veda Andrus, Marie Shanahan, Susan
Luck, Daniel Pesut, Pat Daoust, Jeanne Anselmo, Lynn Keegan, Marlaine Smith, Carla
Mariano, Sara Horton-Deutsch, Stephanie Hope, Christian Ntizimira, Sheila Davis, Cory
McMahon, Viola Karanja, Margaret Zuccarini, and Ann Kurth.
My interdisciplinary palliative care colleagues and mentors at Memorial Sloan
Kettering (MSK) Cancer Center have inspired me beyond comprehension with their
compassion, clinical acumen, leadership, caring, and commitment to alleviate the burden
of serious-health related suffering in the context of advanced cancer and at the end-oflife. My continued clinical practice at MSK throughout my PhD program has been a
source of endless growth, education, and comfort. These nurses, nurse practitioners,
social workers, chaplains, pharmacists, physicians, physician assistants, and ethicists are

vii

the ones who remind me on a daily basis that it is possible to change the world for the
better - just one moment at a time.
I would like to thank my professional ‘families’ affiliated with the Hospice &
Palliative Nurses Association, Partners In Health, Watson Caring Science Institute, Endof-Life Nursing Education Consortium, International Nurse Coach Association,
American Holistic Nurses Association, Conscious Dying Institute, Nightingale Initiative
for Global Health, Sigma Theta Tau International, Health Volunteers Overseas,
Consortium of Universities for Global Health, University of Rwanda, the Rwanda Human
Resources for Health Program, and American Nurses Association. The leadership,
membership, and committees associated with these organizations have provided me with
countless opportunities to advance scholarship and service over the past several years.
Knowing and collaborating with these colleagues who are invested in improving
healthcare and aligned with my professional values has kept me motivated and energized
in exciting ways that have always informed my work.
I want to extend profound gratitude to the organizations and individuals who have
made my PhD program possible through their generosity and financial support. First, I
would like to thank the Robert Wood Johnson Foundation (RWJF) Future of Nursing
Scholars Program. Being a Future of Nursing Scholar has been the highlight of my career
thus far. It is a deep privilege to be counted among a national cadre of junior scientists
who have been supported by this innovative program to combat the national nurse faculty
shortage and advance innovation. In particular, I would like to thank my RWJF mentor,
Dr. Julie Fairman, for being a well of understanding, guidance, and laughter. Dr. Susan
viii

Hassmiller has been a teacher and leader that has created new possibilities for nursing
throughout the national healthcare system. Heartfelt gratitude to Heather Kelly and
Amanda Bastelica, who consistently created spaces of support and friendship during a
very challenging program. Endless thanks to Mary Joan Ladden, Samantha Fotos, and
Denise Scala for their continual demonstrations of help and kindness.
Next, I would like to thank the American Cancer Society for supporting this
research. This study was supported by the American Cancer Society Doctoral Degree
Scholarship in Cancer Nursing Grant (133524-DSCN-19-054-01-SCN; William E. Rosa,
Principal Investigator).
In addition, I would like to express gratitude to the organizations whose grants,
scholarships, and awards provided financial support to attend conferences, disseminate
findings, pursue professional development opportunities, and advance in my doctoral
studies with a sense of fiscal wellbeing, including: Hospice & Palliative Nurses
Foundation (Annual Assembly Conference Scholarships; Certification Scholarship),
Sigma Theta Tau International (Edith Anderson Leadership Education Grant; Graduate
Student Scholarship Award – Upsilon Chapter), American Holistic Nurses Association
(Charlotte McGuire Graduate Scholarship Award), Independence Blue Cross (Nurses for
Tomorrow Scholarship), Penn Nursing Doctoral Student Organization
(Travel/Conference Grants), and the Balm Foundation (Compassionate Empathy Award).
I share this accomplishment with my Penn PhD student colleagues and friends
whose input, listening ears, guidance, iterative feedback, and camaraderie has made this
ix

milestone possible, especially Tarik Khan, Elise Tarbi, Katie Hoskins, Onome Osokpo,
Fanghong Dong, Patrina Sexton Topper, Ellen McCabe, Jacqueline Bannon, and Stephen
Bonett. Acknowledgment also goes to my incredible national cohort of RWJF Scholars
who have blown me away with their friendship and sense of community, in particular,
Alic Shook, Amisha Parekh de Campos, Jessica Goldberg, and Anthony Pho. A special
note of gratitude to my dear friend Amelia Schlak, who - in many ways - has been my
right hand throughout my doctoral studies with her constant love and laughter.
My doctoral program took place at the intersection of a personally
transformational and traumatic experience that changed everything about how I see
myself and the world around me. I would like to thank the gentle and loving humans who
cared for my mind, heart, soul, spirit, and body as I traveled a long road toward healing
and recovery, especially Jeannine Crouse, Suzanne McBride, Mia Morgan, Laurie
Dawson, Akshay Lohitsa, Jan Booth, Robin Sherman, Jay Rothstein, and the many other
support systems and open arms that appeared for me during this fragile time.
My friends and family have been an unyielding source of joy, solace, and love:
Anne Jones, Patricia Moreland, Claude Deering, Zia Inman, Ashley Newman, Hiko
Mitsuzuka, Samantha Haspel, Abigail Stewart, Robin Dunn, Samuel Byiringiro, Tarron
Estes, Carolyn Fulton, Nomi Levy-Carrick, Kathy Madden, Mary Natschke, Versha
Taparia, Fabiola Alegre, Simone Fraser, Allison Applebaum, Paul Kuhn, Holly Shaw,
Jeena Templeton – they are always with me and have been indescribable influences on
me and on this work.

x

To my Ellis… endless thanks for my time spent with her that reminds me to rest,
laugh, run, jump, and smile – and for sitting at my feet as I write these words.
The deepest of gratitude to my entire family. They are the foundation of
everything good in my life. In particular, heartfelt thanks to my mother, Beatrice Rosa,
and father, William Rosa, Sr., who have loved me beyond words. Nothing – absolutely
nothing - would be possible without their love and generosity. How blessed I am to call
them my parents.
Finally – but always first – my husband Michael… he is the starting joy of my
day, the last smile of my evening, the space between my words, and the sound of my
beating heart. His sacrifices, patience, and commitment truly humbles me and makes
anything I want to create in this world a possibility with his unconditional love. He is
whole, perfect, and complete…. and I will spend the rest of my life telling him so.
I have learned that nothing worthwhile in the world arises in isolation. It emerges
out of the love, support, and synergy of those who bravely show up, care to be of service,
and give freely of themselves without expectation of return. All of those mentioned – and
so many others unnamed – have been an integral part of this work and deserve all the
acknowledgment in the world for its completion.
I guess when you’re grateful – you’re just really grateful.
From my heart… thank you.

xi

ABSTRACT

THE ASSOCIATION OF PATIENTS’ ANALGESIC TREATMENT BELIEFS
AND TRADE-OFFS WITH ANALGESIC ADHERENCE BEHAVIORS
AMONG OUTPATIENTS WITH CANCER PAIN
William E. Rosa
Salimah H. Meghani
Pain is one of the most burdensome symptoms for patients with cancer. Per cancer
pain guidelines, opioids remain one of the primary modalities for managing moderate to
severe cancer pain. Analgesic nonadherence is common among cancer patients despite
unmanaged pain symptoms. We investigated how patients prioritized analgesic treatment
beliefs for cancer pain and whether those beliefs predicted objective analgesic adherence
behaviors.
This is a secondary analysis of an existing dataset (n=207) that used a threemonth prospective observational design. Subjects were from outpatient oncology clinics
of a large Philadelphia health system and were > 18 years, self-identified as AfricanAmerican or White, diagnosed with solid tumor or multiple myeloma, and prescribed at
least one around-the-clock analgesic for reported cancer pain.
We conducted three studies to achieve the aims. First, we performed a concept
analysis (Chapter 2) of analgesic nonadherence for cancer pain and qualified its utility in
the context of the United States opioid epidemic. In Chapter 3, we used maximum
difference scaling to identify how patients traded-off on analgesic treatment beliefs.
Utilities (importance scores) were ranked using a k means cluster analysis; clusters were
xii

compared in terms of key variables. Finally, we employed general linear modeling to
evaluate if analgesic belief clusters predicted analgesic adherence behaviors, assessed
longitudinally using electronic medication monitoring while accounting for relevant
confounders (Chapter 4).
Initial results showed beliefs weigh significantly in subjective analgesic tradeoffs. We identified two distinct belief clusters. Side effect severity was the only variable
that significantly differed between clusters. Subjects mostly traded-off based on the
belief, ‘pain medicines keep you from knowing what is going on in your body.’
Addiction was not a top priority. Belief clusters did not predict analgesic adherence.
However, in an adjusted analysis, it was the experiential variables (e.g., side effects, most
potent analgesia, pain relief with analgesics, duration of disease), as well as patients’
race, that were statistically significant in explaining analgesic adherence.
Our findings suggest that experiential variables rather than analgesic beliefs were
associated with analgesic adherence in this sample of cancer outpatients. Additional
studies should explore patients’ cancer pain self-management practices while considering
patient, provider, and system/ structural factors to optimizing cancer pain management.
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CHAPTER 1

Introduction

1

Introduction
Pain has been identified as one of the most common experiences of the cancer
trajectory (Shi et al., 2011). A recent systematic review and meta-analysis of 112 studies
on pain (n=63,533) and pain severity (n=32,261) suggests an estimated two-thirds of
patients with advanced or metastatic cancer report some pain, and up to 38% of patients
report their pain as “moderate” or “severe” (van den Beuken-van Everdingen,
Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 2016). Many patients with moderate to
severe cancer pain require complex analgesic regimens, at times including a combination
of nonopioids, short- and long-acting opioids, and adjuvant prescriptions to effectively
mitigate pain and achieve an acceptable level of function and quality of life (National
Comprehensive Cancer Network [NCCN], 2019; Paice et al., 2016; World Health
Organization [WHO], 1986, 1996, 2018). Unfortunately, there is limited empirical cancer
pain data available. The chronic pain literature often excludes patients with cancer from
the very studies that inform pain management guidelines, drive policies, and establish
prescribing standards for analgesics, including opioids (Meghani & Vapiwala, 2018).
Among the many challenges identified in managing cancer pain is patient
deviation from prescribed analgesic regimens. This concept is known as “nonadherence”.
Nonadherence to analgesics may complicate treatment plans and exacerbate symptoms
among a population negatively impacted by cancer pain. Despite the prevalence of cancer
pain, analgesic nonadherence persists and is poorly understood. A list of key terms
relevant to the phenomenon of analgesic nonadherence and related concepts can be found
in Table 1.
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Analgesic nonadherence behaviors have a number of predictive and covarying
factors. They may be influenced by an individual’s beliefs, preferences, and values
(Gunnarsdottir, Donovan, Serlin, Voge, & Ward, 2002; Jacobsen et al., 2014; Liang et al.,
2013; Meghani & Knafl, 2017; Valeberg, Miaskowski, Paul, & Rustoen, 2016; Ward et
al., 1993); patient and family caregiver hesitancy to use or support the use of analgesics
(Lee et al., 2015; Valeberg et al., 2016); and sociodemographic considerations, such as
race, socioeconomic status, and structural barriers, including insurance coverage (Bryan,
De La Rosa, Hill, Amadio, & Wieder, 2008; Meghani et al., 2014; Meghani, Thompson,
Chittams, Bruner, & Riegel, 2015; Valeberg et al., 2008; Wieder, Delarosa, Bryan, Hill,
& Amadio, 2014) Current clinical interventions to decrease nonadherence rates have not
achieved their aim. For example, Oldenmenger and colleagues reviewed 28 randomized
controlled trials (n=4,735), showing patient education to reduce analgesic nonadherent
behaviors are heterogenous and subpar at best, leading to a significant pain improvement
outcome in less than 20% of all cancer pain patients (Oldenmenger et al., 2018).
Additional studies are required to better inform tailored intervention strategies to
individual and family needs in order to more thoroughly understand analgesic taking
behaviors to prescribed treatment regimens and associated cancer pain burdens.
Understanding Analgesic Nonadherence in the Context of the Opioid Epidemic
Although many healthcare professionals would agree there is an ethical obligation
to treat pain, that duty may be obviated by stigma and policy flux inherent to the opioid
epidemic in the United States. The opioid crisis and its far-reaching implications are
essential to understanding analgesic nonadherence for cancer pain. The crisis has
3

snowballed since the late 1990s (Centers for Disease Control and Prevention [CDC],
2018; Kolodny et al., 2015) accompanied by avid disagreement regarding the future of
pain assessment and ready access to opioid-related interventions. The debate over pain
assessment and the priority of pain treatment using opioids is causing confusion and
misunderstanding about the indication for opioids in mitigating cancer pain; impacting
how patients take their analgesics and how providers prescribe them (American Pain
Society Quality of Care Committee, 1995; Baker, 2017; Meghani & Vapiwala, 2018;
Phillips, 2000; Rummans, Burton, & Dawson, 2018). Major leading reports recognize the
complexities of managing cancer pain, the lack of longitudinal data required to fully
understand the consequences of poorly managed pain, and the struggle of dual loyalties:
reducing the individual burden of cancer pain while minimizing the mounting social
sequelae of opioid use in America (National Academies of Sciences, 2017; National
Academy of Medicine, 2017; National Institutes of Health, 2018). Given the rapidly
changing landscape of opioid use in the setting of pain management, it is natural to
assume that both patient and provider perceptions of opioid use will continue to evolve
given ongoing policy and practice changes across settings and systems.
Purpose and Innovation
The purpose of this research is to explore the relationship between how patients
prioritize their beliefs about analgesic treatment for cancer pain and their objective
adherence behaviors. This purpose is achieved through a concept analysis of analgesic
nonadherence for cancer pain and two research aims, discussed in greater detail in the
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following sections. The anticipated findings will fill a critical gap in the literature related
to how patient beliefs influence nonadherence rates.
The trade-off methodology we will use, known as maximum difference scaling or
‘MaxDiff’, is underutilized in the health care literature and may provide new insights
regarding how patients prioritize their beliefs related to analgesic medication for cancer
pain. While there has been some data reporting how patients make trade-offs related to
analgesic treatment (Meghani, Chittams, Hanlon, & Curry, 2013), MaxDiff provides an
innovative approach to identifying how patients trade-off on their decisions related to
analgesic use. In addressing both research aims we will strive to first identify MaxDiff
derived utilities (importance scores) and, second, we will determine if these utilities
predict objective analgesic taking behaviors via an electronic medication monitoring
system.
Implications may inform how patient deviation from prescribed analgesics is
addressed in the outpatient oncology setting and ways to individualize care based on
patient priorities and beliefs, thereby improving adherence and subsequent patient, safety,
and health outcomes in the future. Given the sample and study focus, this research is
aligned with the NIH Minority Health and Health Disparities Strategic Plan and the
NIH/NINR Strategic Plan’s Areas of Scientific Focus, including symptom science, selfmanagement, and end-of-life and palliative care.

5

Parent Study and Sample Description
This dissertation is based a secondary analysis of existing data (NIH/NINR RC1NR011591: PI Meghani, S.H.) The goal of the parent study was to explain racial and
ethnic disparities in cancer pain outcomes, specifically to elicit trade-offs patients with
cancer pain employ in making cancer pain treatment decisions and the relationship
between patients' stated preferences (using Choice-based Conjoint analysis) and their
adherence to scheduled analgesic treatment using the Medication Event Monitoring
System (MEMS®) (Meghani, Chittams, Hanlon, & Curry, 2013; Meghani, Thompson,
Chittams, Bruner, & Riegel, 2015). The parent study used a prospective observational
design employing repeated measures at baseline (T1) and 3-month follow-up (T2). The
parent study researchers were able to identify analgesic nonadherence as a predictor of
hospitalization (Meghani & Knafl, 2016) and noted analgesic prescribing differences
between African-American and White patients (Meghani et al., 2014). Parent study data
was comprised of various sociodemographic, pain, and illness-related variables, and
identified deviations from prescribed analgesic regimens among patients experiencing
cancer pain in the outpatient oncology setting using multiple adherence measures at T1
and T2. Additionally, patients’ chart data was collected for all subjects in the sample.
Patients were recruited from two outpatient medical oncology services at the
Hospital of the University of Pennsylvania in Philadelphia between December 2009 and
August 2011. Inclusion criteria included patients 18 years or older who self-identified as
White or African-American, were diagnosed with solid tumor (e.g., lung, breast,
gastrointestinal, genitourinary/reproductive) or multiple myeloma, reported cancer pain,
6

and had at least one around-the-clock analgesic prescription. Patients receiving pain
control through a transdermal system (e.g., Duragesic patch) were excluded. Once the
research assistant verified that criteria eligibility were met, the patient’s oncologist
verified eligibility.
A sample of 241 subjects agreed to participate, were deemed eligible, and
completed baseline assessments at T1. There was a 14% attrition rate over the threemonth period due to patient’s death, their being too sick to complete the study, refusal to
participate, or loss to follow-up. Two hundred and seven subjects completed the study at
T2. The sample for this dissertation (n=207) reflects the number of subjects who
completed the parent study since both cross-sectional analysis at T1 and longitudinal
methods involving T2 will be employed.
Specific Aims and Respective Hypotheses
Specific Aims of this dissertation are to:
1. Clarify the concept of analgesic nonadherence for cancer pain and qualify its utility
with respect to the United States opioid crisis. A conceptual definition of analgesic
nonadherence will be identified through a rigorous synthesis of the literature for the
purpose of parsimonious consistency in future use and application (Chapter 2).
2. Elicit the trade-offs patients make about analgesic treatment for cancer pain based on
their analgesic beliefs and concerns (Chapter 3).
2a. Identify and rank MaxDiff-derived patient utilities regarding analgesic beliefs and
concerns.
7

2b. Using utilities identified in 2a., conduct k means cluster analysis to identify
distinct cluster membership among patients based on analgesic beliefs and
concerns.
2c. Describe cluster membership in 2b, by comparing key sociodemographic and
clinical variables.
Hypothesis: There will be unique subsets of cancer patients based on how they
prioritize analgesic treatment beliefs for cancer pain and distinct differences between
how patients prioritize their beliefs that will be decipherable among clusters.
3. Explore whether the previously identified analgesic treatment belief clusters predict
objective analgesic adherence over a three-month period as measured by an electronic
medication monitoring system (MEMS®) while accounting for relevant confounders
(Chapter 4).
Hypothesis: Cluster membership based on analgesic treatment beliefs and concerns
will predict differing levels of analgesic adherence.
Chapter Synopsis
This dissertation uses a “three-paper” format, as described below.
Chapter 1
Chapter 1 herein is an introduction and serves as an overview of analgesic
adherence accompanied by relevant background information, specific aims, and
descriptions of the current and parent study content. Details regarding human subjects, a
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brief overview of methods, variables of interest and instrumentation, as well as the
significance, innovation, strengths, and limitations, are provided.
Chapter 2
Chapter 2 addresses specific aim 1 and seeks to clarify the concept of analgesic
nonadherence for cancer pain and qualify its utility in the context of the opioid crisis for
patients, providers, researchers, and policy makers through an analysis of recent literature
(Rosa, Riegel, Ulrich, & Meghani, 2020). Although the terms ‘analgesic adherence’ and
‘analgesic nonadherence’ are used interchangeably throughout the literature, the way the
concept is operationalized in research often waivers given the study at hand. A theoretical
definition will be provided for the concept that will inform consistency in use and
application in the future. In addition, a conceptual model is illustrated based on the
individual-, provider-, and system-level antecedents and evidence-based consequences
identified during analysis. Among other conclusions discussed in more detail in Chapter
2, this author recognizes that the full impact of the role of analgesic nonadherence is yet
to be determined. Figure 1 provides a conceptual model based on our analysis findings
that serves as a theoretical premise for the remaining chapters.
Brief Overview of Methods and Analysis
Walker and Avant’s (2019) method of concept analysis is utilized to construct a
precise conceptual definition of the phenomenon for future consistency in theoretical and
empirical settings. Their method consists of the following steps: 1) selecting a concept; 2)
determining the aims and purpose of the analysis; 3) identifying all discoverable uses of
9

the concept; 4) describing the concept’s defining attributes; 5) specifying antecedents and
consequences; 6) articulating a model case; 7) identify related cases; and 8) defining
empirical referents.
Chapter 3 Summary
Specific aim 2 is to elicit the trade-offs patients make based on their beliefs about
analgesic use and rank decision-making utilities using MaxDiff scaling and cluster
analysis (Rosa, Chittams, Riegel, Ulrich, & Meghani, 2019). Specific aim 2 will be
achieved using MaxDiff and k means clustering techniques through a cross-sectional
analysis of baseline sample data at T1. Outcomes include descriptive findings that
identify significant differences among how groups of subjects trade-off on analgesic
treatment beliefs in relation to key sociodemographic and clinical variables.
Brief Overview of Methods and Analysis
MaxDiff is a discrete choice experiment that requires subjects to identify the
‘least desirable’ preference related to a given attribute, as well as the ‘best’ or most
preferred option available within a choice set (Finn & Louviere, 1992; Marley &
Louviere, 2005). Thus, it is also known as “best-worst scaling” and is used to identify the
maximum difference in preference between the “best” and “worst” choices available
(Marley & Flynn, 2015). It boasts noted measurement advantages and distinct benefits in
contrast with traditional survey techniques, conjoint analysis, and ranking methods,
which may confuse study subjects with too many options in a given choice set and/or
muddle findings in the absence of clear choice differences (Louviere, Flynn, & Carson,
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2010; Marley & Flynn, 2015). Although MaxDiff has been traditionally used to identify
consumer preferences among brands or items, the case has been made for its increased
use in health care research (Flynn, Louviere, Peters, & Coast, 2007) as social sciences
researchers are using it with greater frequency to better elicit patient preferences in a
number of clinical settings (Feudtner et al., 2015; Louviere, Flynn, & Marley, 2015;
Mooney-Doyle, Deatrick, Ulrich, Meghani, & Feudtner, 2018; October, Fisher, Feudtner,
& Hinds, 2014).
Subjects in this current study were instructed to select the statement that was
“most” and “least” important to him or her in thinking about their pain medications in
order to calculate the maximum difference between competing priorities (Figures 2 and
3). The statements or ‘attributes’ provided to subjects in the parent study questionnaire
were derived directly from the Barriers Questionnaire-II (Ward et al., 1993), a self-report
instrument that evaluates varying aspects of how patients’ beliefs function as barriers to
ideal cancer pain management. The theory undergirding MaxDiff and its application to
this study is described with increased rigor in Chapter 3. The ten attributes assessed using
MaxDiff in the parent study questionnaire can be found in Table 2 under the “Analgesic
Preference” subheading.
Once MaxDiff utilities based on analgesic treatment beliefs were identified, a
cross-sectional cluster analysis of baseline data was performed to describe significant
differences in preference patterns, and cluster membership was detailed in relation to key
sociodemographic and clinical variables. Significant differences between the clusters
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were assessed using chi-squared tests for categorical variables and analysis of variance
(ANOVA) calculations for continuous variables.
Chapter 4
The goal of specific aim 3 is achieved in Chapter 4. Here, we explore whether the
analgesic belief clusters identified through specific aim 2 predict objective analgesic use
as measured by an electronic medication monitoring system while accounting for relevant
confounders. This association was assessed based on analgesic treatment beliefs elicited
at baseline (T1) and the objective analgesic adherence behaviors of patients measured at
follow-up (T2).
Brief Overview of Methods and Analysis
General linear modeling using a backward elimination method will be used with
the analgesic treatment belief clusters (T1) gathered in Chapter 3 functioning as an
independent variable and predictor of objective analgesic adherence (T2 data). A number
of clinically relevant confounders will be taken into consideration within the model, such
as sociodemographic variables, level of social support, and analgesic side effects, to be
discussed in depth in Chapter 4. The outcome variable in this longitudinal analysis will
be objective adherence behaviors tracked with the Medication Event Monitoring System
(MEMS®; Aardex, Switzerland) - a well-established measure within the analgesic
adherence literature (Meghani & Knafl, 2017; Meghani et al., 2015; Oldenmenger et al.,
2007; Oldenmenger, Sillevis Smitt, de Raaf, & van der Rijt, 2017). The MEMS® is
recognized as the ‘Gold Standard’ for measuring adherence in academic research and has
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demonstrated accuracy, ease with use, and patient acceptability, showing benefits in
adherence measurement over numerous limitations associated with other methods (e.g.,
patient report, prescription refill data, biological measurement of medicine or metabolite
levels) (Butler, Peveler, Roderick, Horne, & Mason, 2004; Farmer, 1999; Parker et al.,
2007; Puller, Kumar, Tindall, & Feely, 1989; Vrijens, Urquhart, & White, 2014).
Chapter 5
Chapter 5 will provide overall conclusions through an integrated discussion and
synthesis of findings with implications for clinical practice, education, policy, and future
research, as well as a summary of the major strengths and limitations of the dissertation.
Study Variables, Measures, and Instrumentation
Analgesic Nonadherence. The actual rate of nonadherence is poorly understood
and researchers must frequently negotiate the strengths and weaknesses of available
metrics (Cleemput, Kesteloot, & De Geest, 2002). There are efforts underway to stratify
reporting guidelines for medication adherence, which incorporate multidisciplinary
perspectives, varying patient populations, and diverse geographical areas (De Geest et al.,
2018; Helmy et al., 2017). The measures of adherence in this current study include:
•

Medication Event Monitoring System (MEMS) is an objective metric of medication
adherence through an electronic monitoring device technology (Aardex, Switzerland).
MEMS uses a microprocessor chip implanted in a medication bottle cap to record
the number of times the cap is removed in real-time. This data is subsequently
recorded electronically and can later be analyzed as per the given protocol. The parent
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study measured around-the-clock analgesic adherence as “dose adherence”, defined
as the percentage of the total amount of prescribed doses taken. Methods for dose
adherence calculations and a risk-reducing strategy to minimize the Hawthorne effect
were published previously (Meghani et al., 2015).
Pain-related Variables. A number of pain-related variables are used to assess
pain and pain treatment, medication side-effects, barriers to optimal cancer pain
management, and efficacy of prescribed analgesics based on reported pain severity. Painrelated variables will be measured using:
•

Brief Pain Inventory (BPI-LF) provides a comprehensive evaluation of pain and pain
treatment variables through using a 32-item self-report instrument (Cronbach’s alpha:
0.77-0.91). Of interest, we will be using pain average and pain interference scores,
which are measured on an 11-point scale.

•

Medication Side-effect Checklist (MSEC) is an 8-item scale that identifies the
presence, as well as the type and severity of commonly occurring analgesic side
effects (internal consistency: 0.81). Subjects are asked to rate severity of adverse
effects in the preceding week on a scale of 0-10, with “0” being “no severity” and
“10” being “extreme severity”.

•

Barriers Questionnaire (BQ-II) is a an 8-item revision of the original Barriers
Questionnaire (Ward et al., 1993) that assesses a host of patient-reported cancer pain
management barriers (subscale Cronbach’s alpha: 0.75-0.85, internal
consistency=0.89). Four factors establish the construct validity for the BQ-II: (1)
physiological effects (beliefs about side effects, tolerance concerns, other
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considerations about being unable to identify bodily changes in the setting of strong
pain medicine use); (2) fatalism (fatalistic beliefs about cancer pain and respective
treatment); (3) communication (distracting physicians from a focus on disease
management through pain reporting and the equivocation of a “good” or “strong”
patient with not complaining about pain); and (4) harmful effects (fears of pain
medication addiction and their subsequent damage to the immune system).
•

Pain Management Index (PMI) measures efficacy of a given analgesic prescription in
relation to the reported degree of pain and is based on the analgesic ladder for cancer
pain created by the WHO (1986, 1996). Insufficient pain management is generally
reflected by a negative PMI score while an acceptably adequate analgesic prescription
is indicated by a PMI score of 0 or greater. The PMI is calculated by initial
identification of the analgesic “step” per the WHO cancer pain ladder (1986, 1996,
2018): step 1 = non opioid (nonsteroidal anti-inflammatory agents, acetaminophen);
step 2 = weak opioid (codeine, dihydrocodeine, tramadol, combination agents [e.g.,
oxycodone + acetaminophen]); step 3 = strong opioid (morphine, hydromorphone,
synthetic opioids, Fentanyl). Level of pain is identified per the BPI-LF “worst pain”
rating on the previously described scale of 0-10. While more recent findings have
questioned reliable implications of negative PMI scores, it continues to be a
frequently used measure to evaluate adequacy of prescribed analgesic regimens in
relation to patient-reported cancer pain (Deandrea, Montanari, Moja, & Apolone,
2008; Sakakibara, Higashi, Yamashita, Yoshimoto, & Matoba, 2018).
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Demographic variables. The parent study questionnaire gathered information on
a host of demographic variables (e.g., age, gender, self-identified race, marital status,
education, computer literacy, income, health insurance, occupation, and status of
employment), identified in detail in Table 2. Additional instruments related to health
literacy and social support were used due to potential correlation with medication
adherence, including:
•

Health Literacy Questions (HLQ) is a 3-item scale that has performed well against the
standard health literacy measure, the Test of Functional Health Literacy in Adults
(TOFHLA). The HLQ was used only at T1 of the parent study to assess inadequate
health literacy and asks:
How often do you have someone help you read hospital materials?
How confident are you filling out medical forms by yourself?
How often do you have problems learning about your medical condition
because of difficulty understanding written information?

•

Sarason’s Social Support Questionnaire (SSQ6) assesses two measures of social
support in a 6-item scale (e.g. availability of social support [SSQ-N] and satisfaction
with available social supports [SSQ-S]). The subscales (SSQ-N and SSQ-S) measure
the number of social supports and satisfaction with each of the identified supports
respectively (subscale internal consistency=0.9).
Illness-related Variables. Medical chart data from each patient’s record included:

stage of cancer; time since cancer diagnosis; the number and types of prescribed
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analgesic medications; past history of alcohol or substance abuse; presence of depression;
and comorbidity score.
Table 2 provides a comprehensive list of variables to be used in the dissertation
analyses, the level of data, and how they are operationalized in the data set.
Human Subjects
The parent study was approved by the University of Pennsylvania Institutional
Review Board prior to its execution and all human subjects gave informed consent at that
time. All protected health data was deidentified prior to commencement of this secondary
analysis with no reference to personally identifiable information that may be linked to
research subjects. Therefore, this work does not meet the definition of “human subjects
research” according to the US Department of Health and Human Services, Title 45 CFR
46.102(f). The University of Pennsylvania deemed this dissertation study “exempt” on
these grounds with no need for additional approval (correspondence on file).
Strengths and Limitations
This research maintains a number of strengths. First, a substantial advantage of
this dissertation is the utilization of a rare existing dataset that allows for longitudinal and
objective analyses of analgesic and opioid adherence observed in the outpatient oncology
setting (Meghani et al., 2015; Meghani & Knafl, 2017). In fact, to our knowledge this is
the only dataset that accomplishes these measures in the United States, with one
identifiable exception of a much smaller sample size (Wright et al., 2019). Second, the
sample is roughly 42% African American (African American [n=86]; White [n=121]),
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representing the analgesic treatment beliefs of a traditionally underrepresented racial
minority group. Findings may contribute to further advances in the field of cancer pain
disparities, as well as symptom management disparities at the system level. Third, it
contributes to closing the gap in better understanding the relationship between patient
beliefs and objective adherence behaviors to inform improved interventions in the future.
Last, as previously mentioned, it leverages MaxDiff analysis to provide the first
application of the best-worst scaling method to the field of analgesic nonadherence as far
as we are aware.
There are also several limitations to consider. First among these is the age of the
data; collection was completed in August 2011. However, this time period occurred
during the second wave of the opioid crisis (CDC, 2018) and so we contend that our
findings carry relevant implications for the evolving scholarly and sociopolitical contexts
related to opioids and the opioid addiction epidemic. Second, the sample is limited to
self-identified African American and White patients and, therefore, it will be unable to
address the potential inequities or diverse considerations related to additional racial,
ethnic, or other minority groups who have been previously identified in the disparities
literature (Institute of Medicine, 2003; Meghani, Byun, & Gallagher, 2012). Third, the
parent study used convenience sampling to recruit from the outpatient oncology setting
and does not address how beliefs inform nonadherence behaviors in the inpatient, acute,
long-term, or rehabilitative settings. However, it is impossible to perform MEMS
monitoring with a probability or population-based sample and would be difficult to
recruit random clinical samples.
18

Conclusion
Cancer pain is a detrimental symptom that threatens the health, well-being, and
overall function of affected patients. Although many patients are prescribed analgesic
regimens to alleviate the pain-related experience and associated symptoms, they often
deviate from these recommendations for a wide array of reasons. The literature has
identified several individual/family, provider, and system level covariates of
nonadherence. However, little is understood about how patient beliefs related to analgesic
treatment issues inform their objective adherence behaviors. This study attempts to fill
this gap by employing innovative trade-off methodology techniques to describe patient
belief utilities and correlating them with analgesic adherence behaviors. Findings are
particularly relevant given the current context of opioid crisis and the need for more
effective and equitable pain management strategies across settings and populations.
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Table 1. Key Terms.

•

Analgesics: classified per the World Health Organization (1986, 1996, 2018) cancer
pain ladder as follows:
Step 1: Nonopioids (e.g., nonsteroidal anti-inflammatories)
Step 2: Weak opioids (e.g., codeine, tramadol)
Step 3: Strong opioids (e.g., morphine, Fentanyl)

•

Adherence: the extent to which a person’s behavior (e.g., taking medication),
corresponds with agreed recommendations from a health care provider (Sabate,
2001); often used interchangeably in the literature with the terms ‘compliance’ and
‘concordance’

•

Analgesic nonadherence: a behavioral deviation from a prescribed analgesic regimen;
“a heterogenous construct that lends itself to varied results and interpretations based
on the measures used or dimensions studied” (Meghani & Bruner, 2013, p. e23);
operationalized through a number of subjective and objective measures

•

Maximum differential scaling or ‘MaxDiff’: a type of discrete choice experiment that
requires subjects to identify the ‘least desirable’ preference related to a given
attribute, as well as the ‘best’ or ‘most preferred’ option available within a choice set
(Finn & Louviere, 1992; Marley & Louviere, 2005); also known as “best-worst
scaling” and used to identify the maximum difference in preference between the
“best” and “worst” preferences available (Marley & Flynn, 2015)
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•

Medication Event Monitoring System (MEMS): objective metric of medication
adherence through an electronic monitoring device technology (Aardex, Switzerland);
uses a microprocessor chip implanted in a medication bottle cap to record the number
of times the cap is removed in real-time; has been used in several studies to track
analgesic adherence where the bottle cap openings serve as a proxy for analgesic
taking behavior and are analyzed in comparison to prescribed regimens (Meghani,
Thompson, Chittams, Bruner, & Riegel, 2015; Oldenmenger et al., 2007;
Oldenmenger et al., 2017)
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Table 2. Variables, Level of Data, and Variable Operationalization.
Variable

Level of Data

Operationalization

Demographics
Age

Continuous

Selected from range

Gender

Categorical

1=male
2=female

Marital Status

Categorical

1=married
2=separated
3=divorced
4=widowed
5=never married

Religion

Categorical

1=Christian
2=Muslim
3=Jewish
4=other

Self-identified Race

Categorical

1=African American
2=Caucasian

Education/Years of Formal
Schooling

Categorical

1=no schooling
2=elementary
3=high school
4=college/trade
5=more than college

Employment Status

Categorical

1=full-time outside home
2=part-time outside home
3=full-time at home

32

4=part-time at home
5=retired
6=unemployed
7=other
Household Income

Categorical

1=less than 10k
2=b/w 20k and 30 k
3=b/w 20k and 30k
4=b/w 30k and 50k
5=b/w 50k and 70k
6=b/w 70k and 90k
7=greater than 90k

Insurance Type

Categorical

1=private
2=Medicaid
3=Medicare
4=other/VA/none
5=multiple

Health Literacy Score

Continuous

3-15

Social Support Amount Score

Continuous

0-9 (number of people
identified)

Social Support Satisfaction
Score

Continuous

1-6 (6=most satisfied)

Disease-Related
Cancer Type

Categorical

1=lung
2=breast
3=GI
4=GU/reproductive
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5=multiple myeloma
6=other
7=multiple dx
Cancer Stage

Categorical

1=stage 1
2=stage 2
3=stage 3
4=stage 4

Length of Time Since
Learning of Diagnosis

Continuous

1-120 (months)

Pain-Related
Experience of Pain Present
Due to Present Disease of
Cancer

Categorical

1=yes
2=no
3=uncertain

Length of Pain Due to Present
Disease of Cancer

Continuous

1-120 (months)

Average Pain in the Last
Week

Continuous

0 (no pain) – 10 (worst
imaginable pain)

Pain Functional Interference
Score

Continuous

7-70

Pain Treatment
Number of WHO Step 1
Analgesics

Continuous

0-4 (4 total medications
possible)

Number of WHO Step 2
Analgesics

Continuous

0-4 (4 total medications
possible)

Number of WHO Step 3
Analgesics

Continuous

0-4 (4 total medications
possible)

Total number of analgesics
(excluding co-analgesics)

Continuous

0-4 (4 total medications
possible)
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Co-analgesics

Continuous

0-4 (4 total medications
possible)

Pain Management Index

Continuous

-3 -> +3 (negative=inadequate
pain control, >0=adequate pain
control)

Analgesic Preference
MaxDiff: Cancer pain cannot
be relieved with medications

Continuous

0-100%

MaxDiff: Many people with
cancer get addicted to pain
medicine.

Continuous

0-100%

MaxDiff: Pain medicine
weakens the immune system.

Continuous

0-100%

MaxDiff: Pain medicine can
keep you from knowing
what’s going on in your body.

Continuous

0-100%

MaxDiff: It is important to be
strong by not talking about
pain.

Continuous

0-100%

MaxDiff: Pain medicine
makes you say or do
embarrassing things.

Continuous

0-100%

MaxDiff: If doctors have to
deal with pain, they won’t
concentrate on treating the
cancer.

Continuous

0-100%

MaxDiff: It is easier to put up
with pain than with the side
effects that come from pain
medicine.

Continuous

0-100%

MaxDiff: If you use pain
medicine now, it won’t work
as well if you need it later.

Continuous

0-100%

MaxDiff: If I talk about pain,
people with think I’m a
complainer.

Continuous

0-100%
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Barriers Questionnaire Total
Effects Score

Continuous

27-162

Medication Side Effects Score

Continuous

8-78

Preference to Take Pain
Medicine

Categorical

1=yes
2=no
3=uncertain

Analgesic Adherence
How Much Pain Medication
Taken in the Past Month
(VASdose)

Continuous

1(0%) – 11(100%)

Disease-Related (Other)
Charlson Comorbidity Score

Continuous

0-13

Past History of Substance
Abuse

Categorical

0=no

Past History of Alcohol Abuse

Categorical

1=yes
0=no
1=yes

Presence of Depression

Categorical

0=no
1=yes

General Health
Level of General Health

Continuous

1(best) – 5(worst)

Number of Days in the Last 30
Days That Your Physical
Health Was Not Good

Continuous

0-30 (days)

Number of Days in the Last 30
Days That Your Mental
Health Was Not Good

Continuous

0-30 (days)

36

Health Literacy
Health Literacy Score

Continuous

3-15
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Figure 1. Conceptual Model of Analgesic Nonadherence for Cancer Pain (Rosa, Riegel,
Ulrich & Meghani, 2020).

*This figure depicts the concept of analgesic nonadherence (center), as well as the
concept’s antecedents (left) and consequences (right).
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Figure 2. Maximum Difference Survey Question from Parent Study with Instructions
(Example 1).
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Figure 3. Maximum Difference Survey Question from Parent Study with Instructions
(Example 2).
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CHAPTER 2
A Concept Analysis of Analgesic Nonadherence for Cancer Pain
in a Time of Opioid Crisis1

1

This chapter has been previously published: Rosa, W.E., Riegel, B., Ulrich, C.M., & Meghani,
S.H. (2019). A concept analysis of analgesic nonadherence for cancer pain in a time of opioid
crisis. Nursing Outlook, 68(1), 83-93. doi: 10.1016/j.outlook.2019.06.017 (Science Direct link to
article: https://www.sciencedirect.com/science/article/pii/S0029655419301964?dgcid=author).
Inclusion in this dissertation is protected in accordance with Elsevier’s definition of personal use
as described in their copyright policies (https://www.elsevier.com/about/policies/copyright).
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ABSTRACT

Background: Pain is one of the most common symptoms identified along the cancer
trajectory. Among patients with moderate to severe cancer pain, nonadherence to
prescribed analgesics may complicate treatment plans and exacerbate pain severity.
Nonadherent behaviors are likely due to a number of individual/family, provider, and
system level factors and may lead to negative pain-related outcomes. The purpose of this
concept analysis is to clarify the concept of analgesic nonadherence or cancer pain and
qualify its utility in the context of the opioid crisis.
Method: Walker and Avant’s (2019) method for concept analysis was used. We
integrated empirical evidence, relevant literature, and sociopolitical considerations realted
to the opioid crisis to provide critical and timely analysis. Data were collected from a
search of PubMed, CINAHL, PsychINFO, and Scopus. The search yielded 418 individual
records. Empirical articles using quantitative and qualitative methodologies pertaining to
analgesic nonadherence for cancer pain in adult outpatient settings, written in English,
with an abstract, and published between 2010 and 2018 were considered. Other relevant
literature sources were used if additional criteria were met. A total of 33 records were
selected for detailed review.
Findings: Few studies link analgesic nonadherence to patient outcomes highlighting a
significant literature gap. Given the available evidence, a definitions for analgesic
nonadherence is proposed for future use in research, education, practice, and policy
settings.
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Discussion: The paucity of empirical data combined with the implications of the opioid
crisis and conflicting pain management guidelines create uncertainty about the utility of
analgesic nonadherence. The concept of analgesic nonadherence warrants further
normative and empirical research to clarify the role of opioids and the meaning of
nonadherence in shaping pain-related outcomes within the current sociopolitical
environment.
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A Concept Analysis of Analgesic Nonadherence for Cancer Pain
in a Time of Opioid Crisis
Introduction
According to the Centers for Disease Control and Prevention (CDC; 2018), an
estimated 68% of the 70,200 drug overdose deaths in the United States (US) in 2017
involved the use of an opioid. In fact, the number of drug overdose deaths that implicated
opioids increased six-fold between 1999 and 2017 (CDC, 2018). In the current climate of
the opioid addiction epidemic, various stakeholders are calling for tighter opioid access
policies, more rigorous prescribing standards, and increasingly tailored patient and
community education mechanisms (Christie et al., 2017; National Academies of Sciences
[NAS], 2017; National Academy of Medicine, 2017). While there has been robust focus
on clinician implications related to responsible opioid stewardship, we still lack clear
empirical understanding about the factors that correlate with patients’ use of analgesics.
Opioids remain a keystone of moderate to severe cancer pain management
(National Comprehensive Cancer Network [NCCN], 2019; Paice et al., 2016; World
Health Organization [WHO], 2018), despite discrepant pain management guidelines that
complicate prescribing practices (Meghani & Vapiwala, 2018). According to these
guidelines, many patients with moderate to severe cancer pain require complex analgesic
regimens, at times including a combination of nonopioids, short- and long-acting opioids,
and adjuvant prescriptions, to effectively alleviate pain and improve overall function.
Even though such medication treatment plans are often warranted, many patients deviate
from recommended analgesic regimens or stop taking them altogether.
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Patient nonadherence to prescribed analgesics for cancer pain may compromise a
number of pain-related, health, and safety outcomes (Lee et al., 2015; Manzano, Ziegler,
& Bennett, 2014; Meghani & Knafl, 2016). Cancer patients demonstrate nonadherent
behaviors for a variety of reasons, ranging from individual and family factors (Lee et al.,
2015; Meghani & Bruner, 2013; Meghani, Chittams, Hanlon, & Curry, 2013; Meghani &
Knafl, 2017) to provider and system level barriers (Bryan, De La Rosa, Hill, Amadio, &
Wieder, 2008; Schumacher et al., 2014a; Wieder, Delarosa, Bryan, Hill, & Amadio,
2014; Xu, Luckett, Wang, Lovell, & Phillips, 2018).
The purpose of this concept analysis is to clarify the meaning of analgesic
nonadherence for cancer pain and its use in the literature with respect to the US opioid
crisis. We employ the Walker and Avant (2019) method to deconstruct this concept and
articulate future implications for practice, research, education, and policy. To these
authors’ knowledge, this is the first conceptual analysis of nonadherence specific to
analgesics for cancer pain. A clearer understanding of analgesic nonadherence is crucial
in order to streamline pain management plans and best assist patients in effectively
mitigating their cancer pain burdens in the future.
Background and Significance
The Pain Experience
Pain is a burdensome symptom affecting patients across the cancer trajectory. A
recent systematic review and meta-analysis of 112 studies on pain (n=63,533) and pain
severity (n=32,261) suggests an estimated two-thirds of patients with advanced cancer
report “some” pain, and up to 38% of patients report their pain as “moderate” or “severe”
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(van den Beuken-van Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, & Janssen,
2016). In a longitudinal study exploring cancer survivors’ symptom burden at one-year
postdiagnosis (n=4,903), Shi and colleagues (2011) noted that pain was rated as one of
the top three symptoms negatively impacting health-related quality of life. The authors of
several literature syntheses and landmark reports conclude that cancer pain control may
be suboptimal for many populations and call for enhanced mechanisms to improve
equitable access and delivery of pain care services (Institute of Medicine [IOM], 2003;
Meghani, Byun, & Gallagher, 2012; NAS, 2017; Xu et al., 2018).
Analgesic Use
A number of factors influence analgesic use. Individual beliefs, preferences, and
values are likely to inform nonadherent behaviors. For instance, patients’ beliefs about
analgesics may act as barriers to adherence, such as worries that these medications will
cause physiological or immune system harm or will lead to addiction (Liang, Tung, et al.,
2013; Simone, Vapiwala, Hampshire, & Metz, 2012; Ward et al., 1993). Patient affective
factors, such as emotional distress or anxiety, have been shown to correlate with
nonadherence choices (Jacobsen et al., 2014). In addition to patients, their families and
caregivers also play a significant role in determining analgesic use and the level of
demonstrated adherence (Valeberg, Miaskowski, Paul, & Rustoen, 2016). In fact, distinct
family dynamics and family member hesitancy to use analgesics may mediate patient
adherence behaviors (Lee et al., 2015; Schumacher et al., 2014). The evidence points to
several other considerations required to grasp the full breadth of the concept, such as the
quality of clinician-patient communication and analgesic accessibility (Thinh et al.,
46

2018). Other elements include socioeconomic status and structural barriers, including
insurance coverage (Bryan et al., 2008; Valeberg et al., 2008; Wieder et al., 2014).
The Sociopolitical Milieu
The opioid crisis compounds the phenomenon of analgesic taking behaviors
throughout the national healthcare system. Across the United States, opioid-related events
led to a 64.1% increase of inpatient hospital stays and a 99.4% increase in emergency
department visits between 2005 and 2014 (Rudd, Seth, David, & Scholl, 2016); and in
2015, opioid-related deaths led to overall economic costs estimated at $504 billion or
roughly 2.8% of gross domestic product (The Council of Economic Advisors, 2017). The
crisis marks an era of policy flux, rigorous scientific debate, and multi-agency
collaboration to balance the dual loyalties of reducing the individual burden of cancer
pain while minimizing the mounting social sequelae of opioid use in America (Johnson et
al., 2018; Lamar, 2018; NAS, 2017; National Institutes of Health [NIH], 2018; US
Department of Health and Human Services, 2017). An additional complicating feature is
the recent identification of the critical divide between cancer pain management guidelines
of leading pain organizations (Meghani & Vapiwala, 2018). These inconsistent standards
are due to the daunting lack of accumulated empirical evidence related to cancer pain
management (Meghani & Vapiwala, 2018; NIH, 2014). The concept of analgesic
nonadherence is likely to be best understood by accounting for both the context of the
opioid crisis and the above noted paucity of empirical cancer research.
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Method
Walker and Avant’s (2019) approach to concept analysis (Box 1) is employed to
construct a precise conceptual definition of analgesic nonadherence for cancer pain for
future theoretical and empirical consistency. This method was selected due to its
inclusion of example cases, offering a pragmatic application of the conceptual aspects,
which is essential given the sociopolitical background previously mentioned.
Additionally, this method stresses an iterative approach, promoting continuous
exploration and clarification throughout the process. Finally, since concepts are tentative
in nature, it is crucial to be aware of the cultural, contextual, and social factors that
contribute to the current understanding of the concept at hand (Walker & Avant, 2019).
Therefore, this method allows the reader to relate analysis findings directly to the health
and policy dynamics of the US opioid crisis.
The initial search in PubMed used the MeSH search (‘neoplasms’ OR ‘cancer’
OR ‘cancer pain’ OR ‘cancer related pain’) AND (‘treatment adherence and compliance’
OR ‘medication adherence’ OR ‘patient compliance’) AND (‘analgesics’ OR ‘analgesics,
opioids’ OR ‘narcotics’). Further searches in CINAHL, PsycINFO, and Scopus used the
above terms as keywords. Search terms were defined in collaboration with a librarian at
the University of Pennsylvania Biomedical Library, Philadelphia, Pennsylvania. The
search yielded 418 individual records; duplicates, articles in languages other than
English, and those without an abstract were excluded. Empirical articles using
quantitative and qualitative methodologies and pertaining to analgesic nonadherence for
cancer pain in adult inpatient and outpatient settings, written in English, with an abstract,
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and published between 2010 and 2018 were considered. This time period was chosen
because it spans the current opioid crisis in the United States according to related
literature that emerged during its peak in 2010.
Relevant internationally gathered evidence was employed if it contributed distinct
considerations regarding the concept not addressed in US-based literature. Organizational
pain management guidelines and recommendations, as well as seminal documents outside
of the proposed time frame that continue to influence current analgesic policy and
practice were included. Non-empirical sources included records from Merriam Webster
dictionary (n=2); WHO (n=3); NCCN (n=1); and previous related concept analyses
(n=2). After applying exclusion criteria (Figure 1), a total of 33 records were selected for
detailed review.
Results
Uses of the Concept
The terms adherence and nonadherence are often used interchangeably in the
literature and are facets of the same phenomenon. Other terms such as noncompliance
and nonconcordance have been employed synonymously with nonadherence. The
Merriam-Webster dictionary defines nonadherence as “a lack of adherence” (MerriamWebster, n.d.-b). It is, therefore, essential to grasp the meaning of adherence. Adherence
is “the act, action or quality of adhering” or “steady or faithful attachment” (MerriamWebster, n.d.-a). Previous concept analyses of adherence define it as a “complex,
multidimensional concept impacted by essential elements such as autonomy, selfdetermination, self-efficacy, and communication” (Gardner, 2015, p. 100). Other authors
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emphasize the concept should be considered through a patient-centered lens,
incorporating an individual’s context in how it is evaluated (Alikari & Zyga, 2014). The
WHO (2003) identifies patients’ active participation in medical plan development as a
primary factor that differentiates adherence from the historical notion of compliance. The
WHO (2003) defines adherence as “the extent to which a person’s behavior – taking
medication, … executing lifestyle changes, corresponds with agreed recommendations
from a health care provider” (p. 3).
Analgesics are classified using the WHO (1986, 1996, 2018) cancer pain ladder
and includes step 1 - nonopioids (e.g., nonsteroidal anti-inflammatories); step 2 - weak
opioids (e.g., codeine, tramadol); and step 3 – strong opioids (e.g., morphine, Fentanyl).
Opioids are further classified as long-acting, used to obtain background analgesia for
chronic cancer pain, and immediate-release, taken to treat breakthrough pain and deliver
a quicker onset but shorter duration of pain relief (NCCN, 2019). Some studies include a
patient’s use of coanalgesics, such as antidepressants, anticonvulsants, or corticosteroids,
in understanding predictors of overall nonadherence to pain management
recommendations (Schumacher et al., 2014b). Researchers may focus on adherence
related to one particular step of the cancer pain ladder, such as strong opioids
(Chancellor, Martin, Liedgens, Baker, & Muller-Schwefe, 2012); assess differences in
rates of adherence between nonopioids and opioids (Oldenmenger et al., 2017); focus
primarily on short- or long-acting opioids (Yoong et al., 2013); or include a broad range
of analgesic types (Simone et al., 2012).
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Analgesic nonadherence has been recognized as “a heterogenous construct that
lends itself to varied results and interpretations based on the measures used or dimensions
studied” (Meghani & Bruner, 2013, p. e23). How analgesic nonadherence is empirically
represented varies. For example, some studies define analgesic nonadherence using
subject self-report (Meghani & Bruner, 2013); computed rates of adherence based on
proportions of prescribed doses taken during a given time period (Meghani, Thompson,
Chittams, Bruner, & Riegel, 2015; Rhee et al., 2012); or the number of patients found to
be taking medications as recommended during follow-up appointments (Wieder et al.,
2014). Other researchers study the proportion of doses taken correctly across a given
number of days and within given time intervals per day in relation to medical
recommendations (Oldenmenger et al., 2017) or the amount of opioid taken in
comparison to the amount of opioid prescribed (Nguyen et al., 2013).
Defining Attributes
Attributes are the qualities or features most commonly associated with a concept
(Walker & Avant, 2019). The primary defining attribute of analgesic nonadherence is a
behavior that establishes deviation from a prescribed regimen and may be the result of
both conscious and unconscious influences (Meghani & Bruner, 2013; WHO, 2003).
Such behaviors include filling prescriptions, taking medications as prescribed, attending
scheduled appointments, adopting health behavior change, etc. (WHO, 2003). These
behaviors have been identified as intentional, unintentional, and/or temporal. Intentional
nonadherence is a deliberate choice not to follow a given recommendation; an active
decision reflects a patient’s desire to stop taking their analgesic (Morisky, Green, &
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Levine, 1986). Unintentional nonadherence is an unconscious, relatively passive process
that results in similarly noted behavior (Morisky et al., 1986). Temporality is an
important attribute (Meghani & Knafl, 2016). While some nonadherent behaviors were
found to be habitual, many were influenced by temporal choices and priorities,
fluctuating in accordance with changes to patients’ daily, weekly, or monthly schedules
(Manzano et al., 2014).
Antecedents of Analgesic Nonadherence
Per Walker and Avant (2019), antecedents are events that must be in place prior
to the occurrence of the concept whereas consequences reflect the outcomes of the
concept. For clarity, antecedents have been categorized as individual/family level,
provider level, and system level.
Individual/family level. Identifying patients’ main anchors for decision-making is
central to understanding the driving forces of nonadherent behaviors. In a study of 207
outpatient oncology subjects, about 41% maintained an expectation of pain relief that
primarily determined analgesic decision-making; 11% were most concerned with the type
of analgesic used; roughly 28% were driven by multifactorial determinants including pain
relief and the type and severity of side-effects; and 21% were influenced predominantly
by the type of side effects experienced (Meghani & Knafl, 2017). Longitudinal
qualitative findings echo that the extent to which side effects interfere with a patient’s life
directly coincides with nonadherence behaviors (Manzano et al., 2014). Researchers
using a phenomenological method to elicit the illness narratives of cancer patients (n=18)
suggested that self-perceived benefits of following an analgesic regimen, subjective self52

efficacy, and trust in healthcare providers improved adherence; denial of pain as a
symptom of the disease process posed a barrier (Torresan et al., 2015).
Such concerns, in addition to beliefs and preferences have been well-documented
predictors of nonadherent behavior to analgesic regimens, particularly to opioids
(Chancellor et al., 2012; Rhee et al., 2012). This includes patients’ concerns about the
physiological effects of opioids and worry about dependence or addiction (Jacobsen et
al., 2014; Liang, Chen, et al., 2013; Simone et al., 2012), as well as a belief that doctors
should focus on cancer treatment rather than pain (Rhee et al., 2012). Families and
caregivers play a pivotal role in this phenomenon. Family hesitancy to use analgesics has
been found to mediate patients’ barriers and patients’ adherence (Lee et al., 2015).
Furthermore, family characteristics directly impact the home environment in which
patients live and anchor their analgesic decision-making processes (Schumacher et al.,
2014b).
Various sociodemographic variables have been identified to play a predictive role
in opioid nonadherence. Studies disagree whether males or females demonstrate
nonadherent behaviors more frequently (Liang, Wu, Tsay, Wang, & Tung, 2013; Liang,
Wang, et al., 2013; Nguyen et al., 2013). The same empirical variation occurs in
reference to age, with some investigators noting increased nonadherence among younger
cancer patients (Koyyalagunta et al., 2018); however, older patients may be more likely
to intentionally stop taking medications when they feel better (Meghani & Bruner, 2013).
Other predictors, including income, education and health literacy levels, and level of
prescription coverage have been identified as significant (Meghani & Knafl, 2017;
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Wieder et al., 2014). It appears challenging for patients to take scheduled analgesics at
the correct time intervals due to scheduling issues, forgetfulness, and the complexities of
daily life (Oldenmenger et al., 2017). Of note, increased use of complementary and
alternative medicine for cancer pain management was positively correlated with
unintentional nonadherence (Meghani & Bruner, 2013).
Perhaps one of the most glaring sociodemographic antecedents is race - even
when controlling for insurance and socioeconomic status (IOM, 2003). AfricanAmericans are found to experience increased severity of pain more frequently than White
counterparts (Martinez, Snyder, Malin, & Dy, 2014). Additional studies have shown that
African-Americans are more likely to make nonadherence choices based on the “type of
side effects” experienced rather than “pain relief” (Meghani et al., 2013; Meghani &
Knafl, 2017), which means nonadherence may be more common in African-American
patients due to a higher rate of side effects from inappropriately prescribed analgesics
(Meghani et al., 2014).
Provider Level. Prescribing practices are a major aspect of provider level
antecedents. Patients prescribed around-the-clock (ATC) analgesics other than longacting opioids were more inconsistently adherent (Meghani & Knafl, 2016). Racial
disparity is also a factor at the provider level. African-Americans may receive
inconsistent or erroneous pain assessments by healthcare providers (Wandner et al.,
2014) and are less likely to be prescribed long-acting opioids for pain relief (Meghani et
al., 2015). Meghani et al. (2014) suggest race is a strong predictor of both the type of
opioid prescribed and the severity of analgesic side effects incurred. For example,
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African-Americans have 71% lower odds than Whites of being prescribed oxycodone
versus morphine in the setting of chronic kidney disease (CKD) (Meghani et al., 2014).
This is crucial as morphine accumulates toxic renal metabolites in the setting of CKD that
exacerbate negative side effects and may promote nonadherence. Other minorities, such
as Hispanic patients, have also been noted to be prescribed fewer long-acting opioids than
Whites (Meghani et al., 2015; Wieder et al., 2014).
System Level. Researchers’ interviews with cancer patients (n=42) and family
caregivers (n=20) point to a number of system level antecedents, including complex
clinical care, reimbursement, and analgesic regulation processes; obtaining analgesics;
and the patient/family burden of coordinating care and assuring effective communication
among different providers (Schumacher et al., 2014a). Insurance and prescription
coverage is a substantive predictive factor, with less coverage often afforded racial and
ethnic minorities (Wieder et al., 2014).
Consequences of Analgesic Nonadherence
There are notably few studies that actually link nonadherence to patient or health
utilization outcomes. This is a significant gap in the literature. Notwithstanding, the
consequences identified impact myriad life domains. In a cross-sectional and descriptive
study of 176 patient-caregiver dyads, patients with lower adherence levels who lived in
settings where families were hesitant to use analgesics reported an increased severity of
pain (Lee et al., 2015). Among a sample of 196 outpatient oncology subjects taking
around-the-clock analgesics in a three-month prospective observational study, an
interaction of strong (WHO step 3) opioids and inconsistent adherence was the strongest
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predictor of hospitalization (Meghani & Knafl, 2016). Finally, researchers using an
exploratory longitudinal design and qualitative research methods found that patients
(n=11) who experienced increased pain secondary to analgesic nonadherence sustained
negative impacts to both physical and social functioning, as well as overall quality of life
(Manzano et al., 2014).
Model Case
Take the case of a 40-year-old male diagnosed with stage III colon cancer. He is
prescribed long-acting oxycontin 20mg by mouth twice daily and oxycodone 5-10 mg by
mouth every 4 hours as needed for breakthrough spinal pain due to metastatic disease. He
is terrified of becoming addicted to opioids despite no relevant family or personal history
and he consistently chooses to forego his oxycontin. The patient will take his oxycodone
only when his pain is unbearable. His wife is also adamant he not take opioids due to the
news of the national crisis and fear her husband may suffer an overdose. His current
prescriber insists on him following the regimen as recommended and provides
standardized education in the form of a brochure intended to alleviate his worries. Of
note, this is his first time seeing a pain specialist. His oncologist did not think opioids
were indicated and suggested nonopioid analgesics to manage the patient’s cancer pain
since he is not currently receiving active cancer treatment. This patient’s intentional
nonadherence has led to multiple emergency room visits for pain crises and a rapid
deterioration of quality of life since he is unable to eat, sleep, or work secondary to
uncontrolled pain.
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This case reflects the ways a patients’ salient concerns, family hesitancy,
prescribers’ lack of clarity regarding guidelines, and depersonalized education intersect to
impact a patient’s nonadherence behaviors (Lee et al., 2015; Meghani & Knafl, 2017;
Meghani & Vapiwala, 2018) and subsequent increase in healthcare utilization (Meghani
& Knafl, 2016). Additional cases might describe other challenges, such as analgesic
access given insurance coverage gaps, ineffective coordination between healthcare
services, or how race has been shown to predict nonadherence (Meghani et al., 2014;
Schumacher et al., 2014a; Wieder et al., 2014).
Related Case
According to Walker and Avant (2019), a related case may depict some of the
attributes of a concept but also differs from them when examined more closely; a
particularly relevant approach to this phenomenon. Take the case of a 34-year-old
undomiciled African-American woman recently discharged from a public urban hospital
for uncontrolled pain secondary to her advanced breast cancer. Her primary insurance is
Medicaid. She experienced confusion and nausea to inpatient trials of morphine and then
oxycodone for pain control, finally achieving a desirable response to Fentanyl. While
admitted to the hospital, she felt her pain was being inappropriately managed and
inconsistently assessed. In addition, she has CKD and had been resistant to taking
morphine for this reason. She is ultimately discharged with prescriptions for a 100
microgram/hour transdermal Fentanyl patch to be changed every 72 hours and
hydromorphone 8-12mg by mouth every 3 hours as needed for breakthrough pain. She
denies side effects and endorses tolerable pain on this regimen. After discharge, she is
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told by the local pharmacist that Medicaid will not pay the cost of her prescriptions and
she must use a cheaper medication, such as morphine. The licensed independent
practitioner at her oncologist’s office writes the new prescription that Medicaid will
cover. The patient uses her remaining Fentanyl and hydromorphone, foregoes taking the
morphine due to the adverse effects she previously experienced, and ends up in the
emergency room later that week in a pain crisis. It takes an additional week to gain
insurance approval for the analgesic regimen that works best for her to ensure a safe
discharge – a structural barrier that prevents adherence to the regimen as prescribed.
System-wide challenges, such as analgesic access given insurance coverage issues
and ineffective coordination between prescribers and various healthcare services, makes
adherence impossible (Schumacher et al., 2014a; Wieder et al., 2014). This case also
illustrates how race has been shown to predict nonadherence based on the inappropriate
use of opioids and inaccurate assessment of pain (Meghani et al., 2014).
Empirical Referents
Empirical referents are the means through which the concept can be recognized
and its defining attributes measured (Walker & Avant, 2019). Assessing the underlying
factors that influence nonadherence and determining their basis is essential. For example,
eliciting intentional versus unintentional processes that result in nonadherent behavior
have suggested distinct correlates and decision-making heuristics for each category
(Meghani & Bruner, 2013; Morisky et al., 1986). Objective measures used in the
analgesic adherence literature include the use of an electronic medication event
monitoring system, a tool that records the number of analgesic bottle openings as a proxy
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for adherence, subsequently correlating findings with prescribed analgesic frequency
(Meghani et al., 2015; Oldenmenger et al., 2017).
Incorporating self-reported levels of adherence may capture a key element in
unraveling how nonadherence presents in the cancer pain setting. It has been noted that
subjective analgesic-related beliefs poorly explain objective analgesic taking, which is
influenced more strongly by clinical pain variables (e.g., severity of adverse effects, pain
relief, etc.) (Meghani & Knafl, 2016; Meghani et al., 2015). However, subjective
measures may be helpful to understand medication-taking habits, comparing objective
data to self-reported adherence for increased validity of findings, and recognizing the
various preferences and behaviors that interact to result in nonadherence (Meghani et al.,
2013; Meghani & Knafl, 2017)
Figure 2 provides a model to depict this concept’s defining attributes, antecedents
and consequences, and empirical referents.
Discussion
This analysis has sought to clarify the concept of analgesic nonadherence for
cancer pain and its use in the literature given the current sociopolitical implications of the
opioid crisis. In sum, the literature falls short, leaving us with more questions than
answers. Only a handful of studies have made the link between analgesic nonadherence
and outcomes, which include increased pain severity, higher rates of hospitalization, and
decreased overall quality of life (Lee et al., 2015; Manzano et al., 2014; Meghani et al.,
2014; Meghani & Knafl, 2016). Ultimately, ‘what’ defines optimum adherence behavior
is not clear. This paucity of evidence combined with the practice and policy shifts
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resultant of the opioid crisis invite a new commitment to further empirical studies in this
area. Based on this analysis - while also considering the implications of the current
national context - a more inclusive definition of analgesic nonadherence for cancer pain
is posed: Patient deviation from a prescribed analgesic regimen for cancer pain,
predicted by highly contextual factors within individual/family and societal domains and
potentially complicating both one’s symptom burden and a variety of health outcomes.
There is insufficient reliable evidence to denote a value judgment on analgesic
nonadherence as “good” or “bad”. However, initiatives and policies aimed at mitigating
the crisis are complicating patient access, decreasing the willingness of prescribers to
give opioids, and limiting prescription coverage for patients requiring analgesics,
ultimately impacting patients’ use (Johnson et al., 2018; Lamar, 2018; NAS, 2017). The
question of how to balance social welfare while upholding the moral obligation to
alleviate pain and suffering is at the center of this crisis (NAS, 2017), as well as inherent
to the antecedents of analgesic nonadherence faced by patients.
Current cancer pain management guidelines are limited by a dearth of empirical
research on long-term opioid use to support best practices; the result is conflicting
recommendations from a number of organizations (Meghani & Vapiwala, 2018;
Ranapurwala, Naumann, Austin, Dasgupta, & Marshall, 2019). Although many
guidelines identify opioids as foundational to effective relief for moderate to severe
cancer pain (NCCN, 2019; Paice et al., 2016; WHO, 2018), the CDC discourages opioid
use as a first-line treatment for cancer survivors, who are likely to continue to experience
pain long after active cancer treatment has concluded (Dowell, Haegerich, & Chou, 2016;
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Shi et al., 2011). These competing guidelines are likely to cause confusion among
clinicians, placing patients at risk for subpar, ineffective, and/or risky consequences
(Meghani & Vapiwala, 2018). In understanding analgesic nonadherence, we must ask:
Adherence toward what end? Adherence based on which guidelines and considering what
literature?
Specifically, Meghani and Vapiwala (2018) point out conflicting
recommendations regarding the use of long-acting and immediate-release opioids, which
may also affect adherence behaviors. For instance, they point out that per the NCCN
(2019), long-acting opioids to provide background analgesia should be used in
combination with immediate-release opioids for breakthrough pain; however, the CDC
(Dowell et al., 2016) discourages long-acting opioid use, particularly when immediaterelease opioids are concurrently prescribed. A crucial question is: What does analgesic
nonadherence mean in the context of the CDC opioid guidelines, particularly in the
absence of empirical data for this patient population? In other words, how do providers
ensure timely, effective pain management by addressing adherence concerns for cancer
patients at risk for poor pain control, especially in settings that employ inappropriately
applied guidelines for the population at hand?
The continued study of analgesic nonadherent behaviors in the cancer pain field
given guideline discrepancies and emergent policy debates will be essential to improve
care for affected patients. Furthermore, several studies focus specifically on adherence to
ATC pain regimens (Meghani & Knafl, 2016; Yoong et al., 2013); which may warrant
distinct considerations from those patients prescribed only immediate release analgesics.
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In the trend toward prescribing fewer long-acting scheduled analgesics and using
primarily immediate release medications, the concept of analgesic nonadherence and its
consequences becomes vastly unclear. This paradox requires further investigation to
determine similarities and differences between adherence to both long-acting and
immediate release analgesics. .
Patients’ nonadherent behaviors have been observed in the literature using various
patient-reported surveys and instruments and technologies (Meghani & Bruner, 2013;
Meghani et al., 2013), which makes it difficult to understand and explicate nonadherence
and underlying decision-making processes across studies. Further exploration is needed
to test the interplay of objective and subjective nonadherence measures, as well as
qualitative data that seeks to tease apart the underlying patterns that result in nonadherent
behavior. Additional research might further explore how analgesic adherence choices are
made and the utilities and tradeoffs employed by patients in the decision-making process.
Tailored education for patients, families, and prescribers regarding safe and
effective analgesic use may assist in promoting that the holistic determinants of
nonadherence are addressed. This requires attention to patient-centric models that elicit
individual preferences and values, mitigate risks, and empower prescribers to correctly
apply guidelines. Oldenmenger and colleagues (2018) systematically reviewed 28
randomized controlled trials (n=4,735), showing that standard patient education programs
to reduce analgesic nonadherence may be effective but are correlated with a significant
pain improvement outcome in less than 20% of all cancer pain patients. These results
highlight additional research gaps in this area.
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Overall imperatives include the improvement of pain control, function, and
quality of life and ultimately determining if heightened scholarly focus on nonadherence
has a meaningful role in meeting these outcomes. Furthermore, available evidence is
inconclusive about how to best decrease nonadherent behaviors and understand its role in
predicting patient outcomes.
Limitations
The findings of this concept analysis should be considered in light of the
following limitations. While MeSH terms were used, the diversity of terms chosen to
describe nonadherent behavior may have resulted in the omission of some articles during
the literature review. Though a limited number of organizational recommendations prior
to 2010 were included in the analysis due to their continued influence on analgesic
management of cancer pain and adherence, the selected time frame of the search criteria
(2010-2018) may have overtly limited additional meaningful records for this
phenomenon which possesses an already extensive literature gap. While this analysis was
approached with consideration to the US opioid crisis, broader inclusion criteria in the
future might invite a different understanding of the concept when explored through the
lens of opioid use and availability in the international arena and across diverse cultures.
Conclusion
Cancer pain impacts patients and families by limiting physical and social
function, negatively impacting quality of life, and complicating already taxing oncology
treatment plans. Analgesic nonadherence in the current sociopolitical milieu deserves
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further scholarly dialogue and research to further elicit its relationship to cancer pain; in
short, the role of nonadherence in shaping clinical outcomes must continue to be
addressed. Ultimately, a more detailed understanding of the physiological mechanisms of
analgesic nonadherence may lead to interventions at individual and aggregate levels that
support patients in employing pain medication regimens to more effectively meet their
needs.
It is impossible to sever the complexities related to the opioid crisis from factors
that influence analgesic nonadherence. In fact, the opioid crisis is a crucial and
underexplored antecedent of analgesic nonadherence. The context that birthed the
addiction epidemic, including the beliefs, preferences, and values of both providers and
patients, continues to evolve in an era of stigma and policy fluctuation. The full impact of
the role analgesic nonadherence plays in cancer pain management, particularly within this
current sociopolitical milieu, needs further critical understanding.
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Box 1. Concept Analysis Process (adapted from Walker & Avant, 2019).
1. Select a concept.
2. Determine analysis aims and purpose.
3. Identify all discoverable uses of the concept.
4. Describe the concept’s defining attributes.
5. Specify antecedents and consequences of the concept.
6. Articulate a model case.
7. Identify a related case.
8. Define empirical referents.
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Figure 1. Inclusion/Exclusion Flowchart.
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Figure 2. Conceptual Model of Analgesic Nonadherence for Cancer Pain (Rosa, Riegel,
Ulrich, & Meghani, 2020)

*This figure depicts the concept of analgesic nonadherence (center), as well as the
concept’s antecedents (left) and consequences (right).
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CHAPTER 3
Patient Trade-Offs Related to Analgesic Use for Cancer Pain:
A MaxDiff Analysis Study2

2

This chapter has been previously published: Rosa, W.E., Chittams, J., Riegel, B., Ulrich, C.M.,
& Meghani, S.H. (2019). Patient trade-offs related to analgesic use for cancer pain: A MaxDiff
analysis study. Pain Management Nursing. Epub ahead of print. doi: 10.1016/j.pmn.2019.07.013.
(Science Direct link to article: https://www.sciencedirect.com/science/article/abs/pii/
S1524904219300980?dgcid=rss_sd_all). Inclusion in this dissertation is protected in accordance
with Elsevier’s definition of personal use as described in their copyright policies
(https://www.elsevier.com/about/policies/copyright).
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ABSTRACT

Purpose: Many patients with cancer pain deviate from prescribed analgesic regimens.
Our aim was to elicit the trade-offs patients make based on their beliefs about analgesic
use and rank utilities (importance scores) using maximum difference (MaxDiff) scaling.
We also investigated if there were unique clusters of patients based on their analgesic
beliefs.
Methods: This was a secondary analysis of a three-month, prospective observational
study. Patients (N=207) were self-identified African Americans and Whites, >18 years,
diagnosed with multiple myeloma or solid tumor, and were prescribed at least one
around-the-clock analgesic for cancer pain. MaxDiff analysis allowed us to identify
patients utilities. Second, a cluster analysis assisted in ranking how analgesic beliefs
differed by groups. Third, clusters were described by comparing key sociodemographic
and clinical variables.
Results: Participants’ beliefs were a significant factor in choices related to analgesic use
(chi-square = 498.145, p < .0001). The belief, ‘Pain meds keep you from knowing what is
going on in your body’, had the highest patient endorsement. Two distinct clusters of
patients based on analgesic beliefs were identified; ‘knowing body’ was ranked as top
priority for both clusters. The belief that cancer patients become addicted to analgesics
was moderately important for both clusters. Severity of side effects was the only key
variable significantly different between clusters (p = .043).
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Conclusions: Our findings support tailored pain management interventions that attend to
individual beliefs about cancer pain and analgesic use. Future research should explore the
relationship between analgesic utilities, actual analgesic taking behaviors, and how they
impact patients’ cancer pain outcomes.
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Patient Trade-Offs Related to Analgesic Use for Cancer Pain:
A MaxDiff Analysis Study
The health and policy implications of the current opioid addiction epidemic
require an increased scientific focus on tailored and person-centered pain management
interventions (National Academies of Sciences, 2017; National Academy of Medicine,
2017). This is particularly relevant for patients with cancer, given a well-documented
high prevalence of cancer pain. In a systematic review and meta-analysis of 112 studies
on pain and pain severity, roughly two-thirds of advanced cancer patients reported ‘some
pain’ and about 38% of all cancer patients described their pain as ‘moderate’ to ‘severe’
(van den Beuken-van Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, & Janssen,
2016). Pain has also been endorsed as one of the top three most burdensome symptoms
negatively affecting health-related quality of life for patients (N=4,903) in the year
following cancer diagnosis (Shi et al., 2011). In this time of opioid crisis, there are noted
inconsistencies in pain management guidelines and competing priorities among scientific
and policy institutions that potentially complicate pain-related patient outcomes
(Meghani & Vapiwala, 2018).
Despite much debate, analgesics – and opioids in particular - remain central to the
management of moderate to severe cancer-related pain (National Comprehensive Cancer
Network [NCCN], 2019; Paice et al., 2016; World Health Organization [WHO], 2018).
Although pain management guidelines assist in clarifying the salience of analgesic use
for clinicians, there continues to be a critical paucity of empirical data exploring the
trade-offs employed by patients in their decisions to use analgesics for cancer pain. This
knowledge deficit is critical to address, given the high rates of analgesic nonadherence
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for cancer pain identified in previous studies (Meghani et al., 2014; Meghani & Knafl,
2017; Meghani, Thompson, Chittams, Bruner, & Riegel, 2015; Oldenmenger, Sillevis
Smitt, de Raaf, & van der Rijt, 2017; Rhee, Kim, & Kim, 2012). Inconsistent analgesic
use for cancer pain has been noted as both a strong predictor of increased healthcare
resource utilization (Meghani & Knafl, 2016) and a predictor of poor pain-related and
associated quality of life outcomes (Manzano, Ziegler, & Bennett, 2014).
In response to both the documented need for individualized pain treatment and
notable literature gap regarding patient heuristics, this study uses an innovative analytical
technique - maximum difference (MaxDiff) scaling - to elicit the analgesic trade-offs
patients with cancer employ based on their pain management beliefs. Although MaxDiff
has traditionally been used to identify consumer preferences among brands or items, it
has become an attractive technique to elicit importance scores, also known as utilities, in
relation to phenomena within the social sciences domains (Feudtner et al., 2015; J.J.
Louviere, Flynn, & Marley, 2015; Mooney-Doyle, Deatrick, Ulrich, Meghani, &
Feudtner, 2018; October, Fisher, Feudtner, & Hinds, 2014). In other words, individuals’
trade-offs reflect desirability of a given choice, thereby reflecting the amount of value the
individual derives from that choice.
Prior investigations have used trade-off analysis techniques, such as choice-basedconjoint analysis, to identify analgesic treatment utilities (e.g. trade-offs between type of
analgesic, side-effects type, side-effect severity, % pain relief from using analgesics, and
out-of-pocket cost of analgesics) among cancer outpatients and minority subgroups
(Meghani, Chittams, Hanlon, & Curry, 2013; Meghani & Knafl, 2017). However, to our
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knowledge, this is the first study to understand the role of analgesic beliefs in these tradeoffs. Using MaxDiff analysis, the specific aims of this study are to: (1) identify patient
trade-offs based on analgesic treatment beliefs; (2) rank and describe the utilities
prioritized by patients using a MaxDiff-derived k means cluster analysis; and (3) describe
the clusters in terms of key sociodemographic and clinical variables. Thus, these authors
seek to determine patients’ trade-off on analgesic treatment beliefs, rank each belief
according to the perceived value assigned by the participants, identify if there are any
unique clusters based on participants’ ranking of each belief, and describe the identified
clusters based on participants’ sociodemographic and clinical characteristics.
Methods
Sample and Setting
This is a secondary analysis of an existing dataset (NIH/NINR RC1-NR011591:
PI Meghani, S.H.; (Meghani et al., 2015). The parent study used a three-month
prospective observational design with repeated measures (baseline, T1 and 3-month
follow-up, T2). The primary aim of the parent study was to identify cancer pain
management and analgesic adherence disparities between African-American and White
patients. Convenience sampling was used to recruit from two outpatient medical
oncology services at the Hospital of the University of Pennsylvania, Philadelphia, PA
between December 2009 and August 2011. Approval for the parent study was obtained
from the University of Pennsylvania Institutional Review Board (IRB) and all patients
provided written informed consent.
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Inclusion criteria consisted of patients 18 years or older who self-identified as
White or African-American, were diagnosed with solid tumor or multiple myeloma,
reported cancer pain, and had at least one prescription of oral around-the-clock analgesic.
Patients receiving pain control through a transdermal system were excluded.
A sample of 241 subjects agreed to participate in the parent study. There was an
estimated 14% attrition rate between T1 and T2 and 207 subjects completed the study
(participant recruitment flow diagram published previously in Meghani et al. (2015). Of
note, there was no disproportionate attrition by race or health status in the parent study.
For the purpose of this analysis, data are used for the 207 subjects who completed the
parent study at T2.
The current study was deemed exempt by the University of Pennsylvania IRB as
all data were previously de-identified of protected health information and, therefore, does
not meet the definition of human subjects research.
Measures
Analgesic beliefs and barriers: The Barriers Questionnaire-II (BQ-II) (Ward et
al., 1993), a 27-item self-report instrument, was used to evaluate how patients’ beliefs
function as barriers to optimal cancer pain management (internal consistency
reliability=0.89). The BQ-II evaluates pain management concerns across eight domains,
including fears of analgesic addiction, tolerance, or side effects; cancer pain fatalism; a
desire to be a ‘good patient’; fears that pain will distract the health provider from
focusing on cancer treatment or that analgesics will harm the immune system; and
concern that analgesics mask underlying illness processes.
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Analgesic side-effects: The Medication Side-Effects Checklist (MSEC) was used
to assess the presence and severity of analgesic side-effects (internal consistency
reliability=0.80) (Ward, Carlson-Dakes, Hughes, Kwekkeboom, & Donovan, 1998). The
MSEC identifies eight common side-effects related to analgesic use: constipation,
drowsiness, nausea, vomiting, confusion, dry mouth, stomach irritation, and itching.
Presence of side effects is elicited with a numerical scale, 0-8; severity of side-effects is
measured with a numerical scale, 8-80 (from ‘not severe’ to ‘extreme severity’).
Pain severity and pain-related function: Pain severity was assessed using the
Brief Pain Inventory (BPI). The two subscales of the BPI include a 4-item pain intensity
measure and a 7-item pain-related functional interference score (based on general
activity, mood, walking ability, normal work, relationships, sleep, and life enjoyment)
(Cleeland & Ryan, 1994). Items are scored on a 0-10 scale (no pain – pain as bad as you
can imagine; no interference – worst possible interference). The BPI maintains a
Cronbach’s alpha ranging from 0.77 to 0.91 in its use among cancer patients (Anderson et
al., 2002; Cleeland et al., 1994).
Pain Management Index: Based on the WHO’s cancer pain management
guidelines (1986, 1996, 2018), Pain Management Index (PMI) is frequently used to
measure the adequacy of analgesic treatment in cancer patients. PMI offers a comparative
score of the most potent analgesic used in relation to the patient’s reported pain. PMI is
calculated by taking the most potent analgesia used according to the WHO’s 3-step
cancer pain analgesic ladder and subtracting the patient’s worst pain BPI score. A
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negative PMI implies inadequate analgesic prescription strength given reported pain
level.
Social support questionnaire: Subjects’ level of social support and satisfaction
with perceived social support was elicited using a 6-item instrument (an abbreviated
version of the 27-item Social Support Questionnaire) (Sarason, Levine, Basham, &
Sarason, 1983). There are two parts to the question: first, subjects list the individuals in
their life who provide social support and, second, they provide their satisfaction level
with the support.
Prescribed analgesics: Prescribed analgesics were classified per the WHO (1986,
1996, 2018) cancer pain analgesic ladder. Categories include step 1 (nonopioids, e.g.
nonsteroidal anti-inflammatories), step 2 (weak opioids, e.g., tramadol, codeine), and step
3 (strong opioids, e.g., methadone, oxycodone, morphine).
Sociodemographic and clinical variables: Self-reported sociodemographic data
collected were age, gender, self-identified race, marital status, education, health
insurance, household income, and job status. Clinical variables including stage of cancer,
time since cancer diagnosis, past history of alcohol or substance abuse, history of
depression, and comorbidities were gathered from the patient’s medical record and used
to calculate a Charlson Comorbidity Score (Charlson, Pompei, Ales, & MacKenzie,
1987). Patients rated their general health on a five-point likert scale (from poor to
excellent) and then indicated the number of days in the prior 30-day period in which they
would rate their physical and mental health as “not good”. Pain and treatment related
variables included: the duration of cancer pain and the type and numbers of prescribed
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analgesics and coanalgesics used. Coanalgesics refer to medications used in conjunction
with analgesics to optimize pain control, such as antidepressants, benzodiazepines, or
neuropathic agents.
Statistical Analysis
MaxDiff analysis was completed using JMP Pro 14 software. Descriptive
statistics were computed on Stata/IC 15. First, descriptive statistics were generated for
sociodemographic and clinical variables (e.g., means and standard deviations for
continuous variables, frequencies and percentages for categorical variables).
Trade-Offs Based on Analgesic Beliefs
Trade-offs for the sample (N=207) were derived using a MaxDiff analysis.
MaxDiff is a trade-off methodology derived from Random Utility Theory (Thurstone,
1927). MaxDiff maintains noted measurement advantages over traditional survey
techniques, other ranking methods and some discrete choice analyses methods, which
may confuse participants with too many options in a given choice set and/or muddle
findings by lacking clear measurement differences between choices (Louviere, Flynn, &
Carson, 2010; Marley & Flynn, 2015). Ultimately, MaxDiff allows for (1) increased
discrimination through forced tradeoffs among items and between subjects’ responses on
the given items; (2) demonstrates optimal ease of use for respondents from diverse
education and cultural backgrounds; and (3) avoids scale use bias by requiring
respondents to make choices rather than merely rating the strength of their preferences
(Sawtooth Software, 2019).
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MaxDiff requires subjects to identify both the ‘best’ and ‘least desirable’ option
available within a given set of choices (Finn & Louviere, 1992; Marley & Louviere,
2005). Thus, it is also referred to as ‘best-worst scaling’ and identifies the ‘maximum
difference’ in preference between the ‘best’ and ‘worst’ choices available (Marley &
Flynn, 2015). Subjects in this current study selected the belief statement, also known as
an attribute, that was “most” and “least” important in thinking about his or her pain
medications. Responses allowed us to calculate the maximum difference between patient
responses across eight distinct choice sets. The barriers elicited were based on the
validated Barriers Questionnaire-II (Ward et al., 1993). Table 1 lists the BQ-II domains
(Ward et al., 1993). Abbreviated statements used to represent each of the questionnaire
attributes in the following sections are also provided in Table 1.
MaxDiff analysis results provided measures of marginal probability, which
estimate the probability that a patient conveys a preference for the corresponding attribute
over other listed attributes (SAS Institute, 2019). The marginal probabilities of all
attributes sum to 1.00. MaxDiff analysis also captures measures of marginal utility,
which indicate the perceived value of the corresponding attribute; hence, a larger utility
suggests greater corresponding value to the patient (SAS Institute, 2019). The marginal
utilities provide both positive and negative values and sum to 0. A chi-square likelihood
ratio test was calculated as a part of this initial MaxDiff analysis to elicit whether
patients’ analgesic beliefs were independent of their choices related to pain medications
(p < 0.05).
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Unique Clusters Based on Analgesic Beliefs
MaxDiff-derived utilities were subjected to a k-means cluster analysis. K means is
a prototype-based clustering technique that applies one-level of partitioning using an
unsupervised learning algorithm (Kaufman & Rousseeuw, 1990). K means produces nonoverlapping clusters, such that each data object is assigned to one cluster. This technique
is preferred for this study since hierarchical or fuzzy clustering techniques would use
nested or overlapping cluster membership that would complicate the process of
identifying clear utility trade-offs (Tan, Steinbach, Karpatne, & Kumar, 2019).
A goal with the k means clustering analysis algorithm is to find groups in the data
with a pre-specified number of k centroids (Hastie, Tibshirani, & Friedman, 2009). Data
is then assigned to its closest centroid using a Euclidean distance minimization equation.
Next, centroids are recomputed in an iterative process until they show no further signs of
change (Tan et al., 2019). The goal of clustering was to identify similarities among
groups of individuals in how they prioritize their beliefs related to analgesic treatment.
We selected a 2-cluster model a priori for analysis. Two clusters provided a cubic
clustering criterion (CCC) of -1.95. A lower CCC represents a minimal within-cluster
sum of squares (Tan et al., 2019). An ad hoc quality check confirmed smaller CCCs of 2.31 and -2.18 for 3- and 4-cluster models respectively. A 5-cluster model provided the
largest CCC at -0.24, however, for both parsimony and clarity, as well as the sample size,
2 clusters were used.
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Finally, MaxDiff utility rankings were calculated for each cluster using the
MaxDiff analysis process, as described above (Sawtooth Software, 2013). These rankings
sum to 100.
Cluster Description by Sociodemographic and Clinical Variables
Once clusters were identified and ranking completed, key sociodemographic and
clinical variables were then recalculated for each cluster and statistical tests were used to
identify significant differences between them used Stata/IC 15 (e.g., t-tests for continuous
variables and chi-square for categorical variables).
Results
On average, the subjects were 53.8 years (SD=11.1). The majority self-identified
as White (58.5%), female (56.5%), and were college/trade-school educated (48.8%) or
higher (15.9%) (Table 2). The vast majority of patients were diagnosed with a solid
tumor and less than one-fifth had multiple myeloma. Just under one-third of patients had
Stage IV cancer and more than half rated their general health as “fair” or “poor” in the 30
days preceding data collection. Most patients were prescribed a strong (WHO step 3)
opioid, classified as WHO step 3. In the week prior to the survey, on average patients
reported a “worst pain” score of 6.9 on a 0-10 scale and reported about four different
analgesic side effects.
Trade-Offs Based on Analgesic Beliefs
MaxDiff analysis results for the sample (N=207) include marginal utilities and
marginal probabilities for each of the questionnaire attributes (Figure 1). MaxDiff
likelihood ratio testing suggests that patient beliefs (as represented by the survey
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attributes) are a significant factor in their choices when thinking about pain medicines
(chi-square = 498.145, p < .0001).
‘Knowing body’ and ‘Immune system’ yielded the highest marginal probabilities.
In essence, patients are 23.9% more likely to make trade-offs about analgesic medications
based on ‘Knowing body’ than other competing beliefs. Similarly, ‘Knowing body’ had a
marginal utility of 95.7%, meaning this belief was about twice as important to patients
than ‘Immune system’ or ‘Need it later’, and more than four times as important in making
trade-offs than ‘Addicted to meds’. Not only do patients with cancer identify ‘Knowing
body’ as the most important belief but they are also more likely to make choices based on
it when compared to other beliefs.
Four attributes on the questionnaire yielded negative marginal utilities scores,
indicating no or limited perceived value of these beliefs in relation to pain medicines.
These utilities included, ‘Doctors won’t focus on cancer’, ‘Be strong’; and ‘Say
embarrassing things’. The utility of ‘Complainer’ was minimal at best and could not be
measured using the data platform. Ultimately, patients are markedly less likely to tradeoff based on these four utilities than the beliefs reflected by the other survey attributes.
Utility Ranking: MaxDiff-Derived Cluster Analysis
Using methods described previously, a 2-cluster model was selected. The parallel
coordinate plot (Figure 2) displays the structure of the cluster observation means and
illustrates more explicitly how cluster outcomes differ (discussed in more detail by
cluster). Both clusters ranked ‘Knowing body’ as the most salient utility (Table 3);
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supporting the trade-off findings previously discussed that this belief tends to be the most
important for patients with cancer.
For cluster 1, ‘Side effects’ was ranked as 2nd most important. The least relevant
utilities, ranked 9th and 10th respectively, were ‘Say embarrassing things’ and ‘Won’t
focus on cancer’. This further strengthens the argument that these utilities have little or
no perceived value and are, ultimately, of nominal importance in decisions related to pain
medication. There were some differences noted in cluster 2 rankings. The ‘Need it later’
utility was ranked 2nd among cluster 2 members. Bottom ranked utilities reflected beliefs
related to ‘Complainer’ (9th) and ‘Say embarrassing things’ (10th),
‘Addicted to meds’ was ranked fourth by both clusters, connoting a moderate
level of importance for all patients in the sample. The prioritizing of ‘Addicted to meds’
in the top 50% of utilities by both clusters demonstrates a moderately high belief in
addiction across the sample. While not the most or even the second most important
utility, addiction to analgesics is a consistently relevant factor surrounding pain treatment
beliefs.
Overall, the clusters shared over 50% of the top five ranked utilities in common,
as well as over half of their bottom five (Table 3). These results show that the
prioritization of patient beliefs still varies significantly between clusters, demonstrating
broader substantive differences among how cancer patients’ beliefs inform their thoughts
about analgesic use. This variation reflects the differences in individual beliefs and the
weight given those beliefs when it comes to analgesic use.
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Cluster Description in Terms of Sociodemographic and Clinical Variables
Table 4 shows sociodemographic and clinical variables by cluster. Less than half
of cluster 1 (n=53) self-identified as African-American (43.4%) and the majority were
female (60.4%). This group rated their “worst pain” as slightly more severe than cluster
2. Additionally, cluster 1 patients endorsed a significantly higher severity related to
analgesic side effects than cluster 2 (p = 0.043). On average, cluster 1 patients were
prescribed roughly two analgesic medications to alleviate their cancer pain, the majority
of which were a strong opioid (WHO step 3). They also reported experiencing about four
different analgesic side effects. The majority of cluster 2 (n=154) self-identified as White
(59.1%) and female (55.2%) (Table 4). The number of analgesics (including strong
opioids) prescribed and the number of side effects experienced were very similar to
cluster 1. Patients in cluster 1 and cluster 2 did not vary significantly in age, gender, race,
or other sociodemographic variables (Table 4). Other clinical variables included in the
analysis showed no statistically significant differences.
Discussion
In our study, we first sought to identify patient trade-offs based on analgesic
treatment beliefs using a MaxDiff analysis. We subsequently ranked the utilities
prioritized by patients using a k means cluster analysis and then described the clusters in
terms of key sociodemographic and clinical variables. To our knowledge, this is the first
study to use the MaxDiff methodology in this context. Previous studies have noted that
patients with cancer pain stop taking their analgesics for a number of reasons. Some of
these include the severity of side effects (Manzano et al., 2014; Meghani & Bruner, 2013;
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Meghani et al., 2015); concern regarding the physiological consequences of opioid use,
such as dependence or addiction (Jacobsen et al., 2014; Simone, Vapiwala, Hampshire, &
Metz, 2012); a firm conviction that clinicians should focus on treating the cancer rather
than pain (Rhee et al., 2012); and the hesitancy of patients’ family and caregivers to use
analgesics (Lee et al., 2015; Schumacher et al., 2014). Our analysis suggests that patient
trade-offs based on certain beliefs about cancer pain management yield a significant
influence in their choices about analgesic use. This finding is consistent with previously
demonstrated empirical links between analgesic beliefs and analgesic nonadherence
behaviors (Liang et al., 2013; Meghani & Bruner, 2013; Torresan et al., 2015; Valeberg,
Miaskowski, Paul, & Rustoen, 2016). Despite these study findings, we still know little
about how patients make the decision to use analgesics based on their beliefs.
A striking result was that the belief, ‘Many people with cancer get addicted to
meds’, was not a top priority for participants. In fact, this utility was ranked 4th and found
to be of only moderate importance among both clusters. One may have anticipated a
higher importance score related to addiction beliefs given these data were collected at the
height of the opioid addiction epidemic. Despite some studies that suggest a worry about
dependence or addiction to opioids as significant in the patient decision-making process
(Jacobsen et al., 2014; Liang et al., 2013; Simone et al., 2012), researchers have argued
that addiction concerns do not explain objective analgesic adherence in the cancer pain
population (Meghani et al., 2015). In addition, this finding is consistent with other
evidence showing that although a significant number of patients express some concern
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about addiction to opioids, this belief is also not correlated with subjective measures of
adherence (Rhee et al., 2012).
Participants across the sample consistently prioritized the ‘Pain meds keep you
from knowing what is going on in your body’ utility with the highest level of importance.
This result validates the emphasis patients place on knowing their own bodies (‘Knowing
body’) in thinking about their pain medications. Furthermore, this belief may yield more
significant trade-off power over other beliefs and may directly correlate with a patients’
likelihood to use analgesics to mitigate their cancer pain burden. Future research should
examine these issues. This finding of knowing one’s body emphasizes how important it
is to cancer patients to have a firm understanding of their underlying physiological
processes.
The high relevance of knowing one’s body validates the results of several
previous empirical studies. Investigators found that cancer patients with higher rates of
intentional analgesic nonadherence were more likely to agree with the ‘Knowing body’
statement (Meghani & Bruner, 2013). In a recent survey of patients with different
cancers, the presence of pain was significantly linked to the status of disease (Rau et al.,
2017), which may explain how patients use pain to better understand their bodies and
why they stop taking analgesics accordingly. Other findings suggest that some patients
deny pain as a symptom of disease, which may increase barriers to analgesic utilization
(Torresan et al., 2015). Another study by Liang and colleagues (2013) showed that about
one-third of patients believe opioids should only be used late in the disease process,
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consistent evidence that analgesics may become more acceptable once patients feel they
have a clearer understanding of what is going on in their bodies.
Consistent with previous research that associates increased side effects and side
effects severity with decreased analgesic adherence (Manzano et al., 2014; Meghani &
Bruner, 2013; Meghani et al., 2014), our cluster analysis findings highlights the
importance of addressing patients’ side effects when using analgesics for cancer pain. In
addition, the severity of side effects also differed significantly between cluster 1 and
cluster 2, further suggesting that the utility of ‘Side effects’ may be a salient concern for
some and not others. For example, an earlier study involving this sample concluded that
more than a quarter of patients were found to make trade-offs based on multiple
concerns, including both type and the severity of side effects (Meghani & Knafl, 2017).
‘If you use pain medicine now, it won’t work when you need it later’ was ranked
among the top two utilities for cluster 2. In other words, a worry about tolerance to
analgesics may be a likely concern for patients with cancer pain. This utility is informed
by the belief that if patients with cancer pain take analgesics whenever they need it, then
those same medications will not be effective when the pain increases in severity and the
need for relief is more substantial. This correlates with a study that showed a majority of
patients agree that using an opioid in earlier disease stages will prevent its optimal effect
later (Liang et al., 2013). Some trade-offs, such as ‘Won’t focus on cancer’, ‘Be strong’;
‘Say embarrassing things’; and ‘Complainer’, were found to have low utility. These
findings are in alignment with a previous study showing that these beliefs tend to have
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less importance among patients with cancer pain than ‘Knowing body’ or ‘Immune
system’ (Valeberg et al., 2016).
Clinical Implications
A number of relevant clinical implications are suggested. First, clinicians who
prescribe and administer analgesics to treat cancer pain should elicit patients’ analgesic
beliefs in order to ensure safe use and minimize adverse outcomes. The analgesic
treatment priorities and beliefs of patients may not always be aligned with the priorities
of clinicians, such as the case with addiction concerns. Second, analgesic regimens
should be determined in partnership with patients to ensure patients’ beliefs are optimally
considered in creating prescription pain treatment plans. Prescribing in partnership
requires the integration of patient-centered care with evidence-based pain guidelines,
which are currently severely lacking, specially for opioid pain management for cancer
pain (Meghani & Vapiwala, 2018). Third, optimizing nonopioids and weak opioids that
cause fewer adverse effects per the WHO (1986, 1996) cancer pain ladder may address
patients’ beliefs. However, it must be emphasized that many guidelines continue to
suggest the use of strong opioids in the treatment of moderate to severe cancer pain
(NCCN, 2019; Paice et al., 2016; WHO, 2018). Fourth, our findings support well-cited
recommendations in academia and policy calling for tailored patient education related to
opioid use, risks, and benefits (Christie et al., 2017; National Academies of Sciences,
2017; National Academy of Medicine, 2017; Oldenmenger et al., 2018). As future
research elucidates the link between individual beliefs and actual analgesic taking
behaviors, interventions related to analgesic prescribing and education should aim to
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become more patient-centric. It is imperative that the relationship between beliefs and
analgesic adherence be further clarified for the sake of improved patient safety and health
outcomes, particularly in the current sociopolitical milieu of the opioid addiction
epidemic.
Limitations
There were several limitations to consider. First, the data was collected between
2009 and 2011; this time period, however, overlapped with the second wave of the opioid
crisis (Centers for Disease Control & Prevention, 2018), making the findings highly
relevant to the current sociopolitical milieu. Second, the sample is limited to patients who
self-identify as either African-American or White, excluding the utilities of patients from
other diverse backgrounds. Additional studies might examine if differences exist among
other ethnic, racial, and minority populations. Third, the parent study questionnaire
provided patients with ten attribute statements assessed through eight different choice
sets. There are a broad variety of attributes that were likely not included in our study. In
the future, researchers may consider a more extensive attribute list, as well as the
integration of qualitative methods to validate findings and cultivate a deeper
understanding of this phenomenon. Finally, provider-, family-, and system-level factors
and their influence on analgesic use were not accounted for in the MaxDiff analysis.
Ongoing investigations might combine family and provider factors along with patient
utilities to describe differences in trade-offs, as well as the link to analgesic taking
behaviors.
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Conclusion
There is much yet to be explored about how beliefs and resultant utilities factor
into analgesic use and overall adherence in the management of cancer pain. In better
understanding the trade-offs made by patients, prescribers have improved opportunity to
tailor pain treatment strategies to individual needs. The current climate of the opioid
crisis and its broad implications in practice, policy, and research require investigators and
clinicians to cultivate a deeper understanding of how patients’ beliefs inform their
decision-making processes around analgesic taking behaviors.
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Table 1. Attributes for MaxDiff Analysis with Abbreviations Based on Barriers
Questionnaire-II (BQ-II) Domains.
BQ-II Domains
(Ward et al., 1993)

Attributes for MaxDiff Analysis

Abbreviated Attribute
Statement

1. Fear of addiction.

Many people with cancer get
addicted to pain meds.

Addicted to meds

2. Fear of tolerance.

If you use pain medicine
now, it won’t work when
you need it later.

Need it later

3. Fear of side effects.

It is easier to deal with the
pain than the side effects that
come from the pain meds.

Side effects

Pain meds make you say or
do embarrassing things.

Say embarrassing
things

4. Fatalism about cancer pain.

Cancer pain cannot be
relieved with medications.

Cannot be relieved

5. Desire to be a good patient.

If I talk about pain, people
will think I’m a complainer.

Complainer

It is important to be strong
by not talking about pain.

Be strong

6. Fear of distracting health
provider from treating
cancer.

If doctors have to
concentrate on pain they
won’t focus on treating the
cancer.

Won’t focus on
cancer

7. Fear that analgesics impair
the immune system.

Pain meds weaken the
immune system.

Harm immune
system

8. Concern that analgesics
may mask ability to
monitor illness symptoms.

Pain meds keep you from
knowing what is going on in
your body.

Knowing body
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Table 2. Relevant Sociodemographic, Illness, and Pain-Related Characteristics (n=207).
Variable

n(%)1

Range

Age

23-75

Gender

Male

90 (43.5)

Female

117 (56.5)

African-American

86 (41.5)

White

121 (58.5)

Self-identified race

Education

Household income

Job status

Primary Insurance2

Mean (SD)

53.8 (11.1)

Elementary

3 (1.5)

High School

70 (33.8)

College/Trade school

101 (48.8)

More than college

33 (15.9)

< 30,000

73 (35.3)

30,000-50,000

36 (17.4)

50,000-70,000

37 (17.9)

70,000-90,000

24 (11.6)

>90,000

37 (17.9)

Full-time outside home

43 (20.8)

Part-time outside home

12 (5.8)

Full-time at home

4 (1.9)

Part-time at home

4 (1.8)

Retired

44 (21.3)

Unemployed

25 (12.1)

Other

75 (36.2)

Private

107 (51.9)

Medicare

41 (19.9)

Medicaid

27 (13.1)
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Multiple

25 (12.1)

Other

6 (2.9)

Health literacy

3-15

13.1 (2.6)

Social support

0.17-9.00

3.7 (2.1)

Cancer type

Lung

32 (15.5)

Breast

38 (18.4)

Gastrointestinal

31 (15.0)

Genitourinary/reproductive

25 (12.1)

Multiple myeloma

34 (16.4)

Other solid tumors

47 (22.7)

I

20 (9.7)

II

33 (15.9)

III

37 (17.9)

IV

64 (30.9)

Unknown or unsure

53 (25.6)

Cancer stage

Time since cancer
diagnosis

1-120 months

36.7 (35.5)

Charlson comorbidity
index

0-13

General health

Excellent

9 (4.3)

Very good

23 (11.1)

Good

63 (30.4)

Fair

77 (37.2)

Poor

35 (16.9)

4.3 (2.6)

Physical health not good 0-30
(within past 30 days)

14.7 (10.7)

Mental health not good
(within past 30 days)

9.5 (10.7)

0-30
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History of substance
abuse

Yes

35 (16.9)

No

172 (83.1)

Presence of depression

Yes

87 (42.0)

No

120 (58.0)

Index analgesic

WHO Step 1

19 (9.2)

WHO Step 2

22 (10.6)

WHO Step 3

166 (80.2)

Average pain (last
week)

0-10 (no pain - pain as bad as
you can imagine)

4.9 (2.1)

Pain-related functional
interference score

7-70 (does not interfere interferes completely)

Pain Management Index

-2

5 (2.4)

-1

13 (6.3)

0

92 (44.4)

1

63 (30.4)

2

31 (15.0)

3

3 (1.4)

35.2 (15.9)

Barriers Questionnaire
(BQ-II)

0-135

66.8 (20)

Number of analgesic
side-effects (MSEC)

0-8

3.8 (2.4)

Severity of analgesic
side-effects (MSEC)

8-80 (not severe – extremely
severe)

1

No missing values unless otherwise noted. SD: Standard deviation.

2

One value missing.
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25.2 (15.0)

Table 3. MaxDiff Utilities Ranked by Cluster
Cluster 1 (n=53)
Mean (SD)
Knowing body

Cluster
Rank
Order
14.204

1

Cluster 2 (n=154)
Mean (SD)
Knowing body

(6.266)
Side effects

13.899

(6.699)
2

Need it later

(5.573)
Be strong

12.353

11.949

3

Harm immune system

11.380

4

Addicted to meds

10.045

5

Cannot be relieved

8.254

6

Won’t focus on cancer

6.579

7

Side effects

6.344

8

Be strong

4.993

4.333
(4.202)

9

Complainer

(5.687)
Won’t focus on cancer

9.830
(4.730)

(5.466)
Say embarrassing things

9.838
(8.198)

(5.751)
Cannot be relieved

11.907
(6.382)

(7.569)
Harm immune system

13.560
(9.040)

(6.415)
Complainer

14.137
(6.568)

(9.015)
Need it later

15.015
(7.415)

(7.603)
Addicted to meds

17.388

2.066
(3.064)

10

Say embarrassing things

(5.286)

1.927
(1.959)

*The middle column provides a rank order numbered 1-10. The two left-hand columns
provide the order of cluster 1 utilities based on rescaled MaxDiff probabilities. Similarly,
the two right-hand columns provide the order of cluster 2 utilities.
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Table 4. Key Clinical Variables by Cluster.
Variable

Cluster 1 (n=53)

Cluster 2 (n=154)

P-value[a]*

Age (years)

54.2 (12.5)

53.7 (10.7)

0.798

Duration of disease (months)

30.5 (29.4)

38.9 (37.2)

0.138

Charlson Comorbidity Score (013)

4.4 (2.3)

4.3 (2.8)

0.725

Social Support Amount (0.179.00)

4.1 (2.3)

3.6 (2.0)

0.102

General health not good (number
of days within last 30 d)

3.5 (1.0)

3.5 (1.1)

0.862

Physical health not good (number
of days within last 30 d)

15.7 (11.3)

14.4 (10.5)

0.439

Mental health not good (number of
days within last 30 days)

8.3 (10.1)

9.9 (10.9)

0.333

Pain Management Index (-2 - +3)

0.5 (0.8)

0.6 (1.0)

0.687

Number of analgesics (excluding
coanalgesics) WHO Step 1

0.3 (0.5)

0.2 (0.4)

0.410

Number of analgesics (excluding
coanalgesics) WHO Step 2

0.2 (0.4)

0.3 (0.6)

0.087

Number of analgesics (excluding
coanalgesics) WHO Step 3

1.7 (1.0)

1.5 (0.8)

0.099

Total number of analgesics
prescribed (excluding
coanalgesics)

2.2 (1.0)

2.0 (0.8)

0.309

Worst pain (0-10)

7.1 (2.0)

6.8 (2.5)

0.530

Number of analgesic side effects
(MSEC, 0-8)

4.1 (2.4)

3.7 (2.5)

0.266

Mean (SD)
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Severity of side effects (MSEC, 080)

28.8 (15.6)

24 (14.6)

0.043

Health literacy (3-15)

13.3 (2.7)

13.0 (2.6)

0.413

Barriers Questionnaire-II (BQ-II,
0-135)

63.7 (19.4)

67.8 (20.2)

0.200

Frequency (%)
Race

0.751

African-American

23 (43.4)

63 (40.9)

White

30 (56.6)

91 (59.1)

Gender

0.512

Male

21 (39.6)

69 (44.8)

Female

32 (60.4)

85 (55.2)
0.397

Marital Status
25 (47.2)

85 (55.2)

Separated

5 (9.4)

11 (7.1)

Divorced

10 (18.9)

22 (14.3)

Widowed

4 (7.5)

4 (2.6)

Never married

9 (17.0)

32 (20.8)

Married

Education

0.922

Elementary

1 (1.9)

2 (1.3)

High school

16 (30.2)

54 (35.1)

College/trade school

27 (50.9)

74 (48.1)

More than college

9 (17.0)

24 (15.6)

Household income

0.861

< 30,000

21 (39.6)

52 (33.8)

30,000-50,000

9 (17.0)

27 (17.5)
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50,000-70,000

7 (13.2)

30 (19.5)

70,000-90,000

6 (11.3)

18 (11.7)

>90,000

10 (18.9)

27 (17.5)
0.731

Primary insurance
Private

25 (47.2)

82 (53.6)

Medicare

13 (24.5)

28 (18.3)

Medicaid

6 (11.3)

21 (13.7)

Multiple

1 (1.9)

5 (3.3)

Other

8 (15.1)

17 (11.1)
0.934

Job status
Full-time outside home

11 (20.8)

32 (20.8)

Part-time outside home

4 (7.5)

8 (5.2)

Full-time at home

1 (1.9)

3 (1.9)

Part-time at home

0 (0)

4 (2.6)

Retired

11 (20.8)

33 (21.4)

Unemployed

6 (11.3)

19 (12.3)

Other

20 (37.7)

55 (35.7)
0.721

Cancer stage
I

2 (3.8)

11 (7.1)

II

7 (13.2)

17 (11.0)

III

6 (11.3)

25 (16.2)

IV

17 (32.1)

43 (27.9)

Unknown or unsure

21 (39.6)

58 (37.7)
0.541

9 (17.0)
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23 (14.9)

Cancer type

12 (22.6)

Lung

9 (17.0)

Breast

4 (7.5)

Gastrointestinal

7 (13.2)

Genitourinary/reproductive

12 (22.6)

26 (16.9)
22 (14.3)
21 (13.6)
27 (17.5)
36 (22.7)

Multiple myeloma
Other solid tumors
History of substance abuse

0.659

Yes

10 (18.9)

25 (16.2)

No

43 (81.1)

129 (83.8)

*p-values are based on t-tests for continuous variables; chi-squared for categorical
variables.
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Figure 1. MaxDiff Marginal Utility and Marginal Probability.

*Attributes are listed in descending order by marginal utility (left) and marginal
probability (right).

117

Figure 2. Parallel Coordinate Plot: MaxDiff Cluster Means.

*Observation means of rescaled marginal probabilities by cluster. This plot presents
utilities by cluster membership and is a visual representation of the data found in Table 3.
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CHAPTER 4

The Association Between Analgesic Treatment Belief Clusters and
Electronically-Monitored Analgesic Adherence for Cancer Pain

119

ABSTRACT

Objectives: To determine if clusters based on cancer patients’ analgesic treatment beliefs
predicted objective analgesic adherence as measured by an electronic medication
monitoring system while accounting for relevant confounders.
Sample and Setting: The sample (N=207) consisted of outpatient oncology patients, >
18 years, self-identified as White or African-American, diagnosed with solid tumor or
multiple myeloma, and prescribed at least one around-the-clock analgesic prescription for
reported cancer pain.
Methods and Variables: This is a secondary analysis of an existing dataset. We applied
general linear modeling with a backward elimination approach to determine if previously
identified analgesic treatment belief clusters were associated with adherence behaviors.
Results: Significant explanatory factors were experiential in nature and included
sociodemographic, clinical, and pain-related variables (p < 0.05), explaining 21% of the
variance in analgesic adherence. Analgesic belief clusters were not predictive of
adherence.
Implications for Nursing: Future research should examine sociodemographic and other
clinical factors, as well as the influence of analgesic treatment beliefs, to better
understand analgesic adherence behaviors.
Knowledge Translation: Oncology nurses should address the experiential factors
affecting analgesic adherence, become aware of evolving pain management strategies
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amid the opioid epidemic, and understand how the notion of ‘adherence’ may change
given increased emphasis on ‘as-needed’ analgesic relief for cancer pain.
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The Association Between Analgesic Treatment Belief Clusters and
Electronically-Monitored Analgesic Adherence for Cancer Pain
The majority of patients with cancer report pain and as many as 38% report their
pain as moderate to severe (Shi et al., 2011; van den Beuken-van Everdingen,
Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 2016). Although there is a lack of data
on outcomes related to long-term opioid use for cancer pain (Meghani & Vapiwala,
2018), a number of cancer pain guidelines continue to identify opioids as a core
component of moderate to severe cancer pain management (National Comprehensive
Cancer Network [NCCN], 2019; Paice et al., 2016; World Health Organization [WHO],
2018). While some pain management guidelines promote the use of complementary and
alternative strategies (Dowell, Haegerich, & Chou, 2016; NCCN, 2019), their
affordability may be unmanageable for some and several systematic reviews have noted
insufficient evidence to support their clinical efficacy in alleviating cancer pain (Hetkamp
et al., 2019; Kim, Loring, & Kwekkeboom, 2018; Kim, Kang, & Lee, 2018; Shin et al.,
2016; Wayne et al., 2018). Thus, analgesic use - and opioid use in particular - remains a
primary modality for achieving moderate to severe pain control in the cancer population.
Although there are a number of national initiatives underway that focus on advancing
pain science from the provider perspective (National Academies of Sciences, 2017, 2020;
National Academy of Medicine, 2017), we still know little about the predictors of
patients’ actual analgesic taking behaviors.
Given the opioid epidemic and its healthcare implications, the phenomenon of
analgesic adherence requires better understanding. Patients who experience less pain
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relief with analgesic use or higher side effect severity are typically less adherent to
prescribed analgesic regimens, whereas those prescribed a strong opioid (classified as
WHO step 3) or a long-acting opioid show higher levels of adherence (Meghani,
Thompson, Chittams, Bruner, & Riegel, 2015). Patient beliefs have been shown to
predict adherence behaviors. For example, patients who believed their doctor should
focus on curing illness over treating pain demonstrated increased adherence behaviors.
Inconsistent analgesic adherence for cancer pain has been correlated with increased
hospitalization rates (Meghani & Knafl, 2016), as well as poor pain and quality of life
outcomes (Manzano, Ziegler, & Bennett, 2014). In addition, the patients with higher
hospitalization rates shared a belief that pain medicine can harm the immune system
(Meghani & Knafl, 2016).
Understanding how patient beliefs inform decisions to use prescribed analgesia is
an important aspect of improving pain management strategies and subsequent outcomes
(Miaskowski et al., 2001). Researchers have identified distinct patient clusters based on
how patients make trade-offs (e.g. type of analgesic, type and severity of side-effects,
amount of expected pain relief, and out of pocket costs) in considering analgesic
treatment for cancer pain (Meghani & Knafl, 2017). Using choice-based conjoint
analysis, these researchers found that a majority of patients may be motivated
predominantly by a single salient concern in their decision to use analgesia for cancer
pain (Meghani & Knafl, 2017).
We previously found two unique clusters of patients based on how they
prioritized their beliefs about analgesic treatment for cancer pain (Rosa, Chittams, Riegel,
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Ulrich, & Meghani, 2019). These analgesic treatment belief clusters were identified using
a decision-making trade-off methodology known as maximum difference scaling to elicit
what beliefs are most important to patients when thinking about analgesic use for cancer
pain management. Patients in our study were most likely to trade-off based on the belief
that taking pain medicine would keep patients from knowing what is going on in their
body (Rosa et al., 2019). A belief that patients who take analgesic for cancer pain become
addicted was only moderately important across the sample. (Rosa et al., 2019). Our
specific aim for this paper is to assess whether these unique analgesic belief clusters
predict objective analgesic use as measured by an electronic medication monitoring
system while accounting for relevant confounders.
Methods
Design and Study Population
This study is a secondary analysis of existing data (NIH/NINR RC1-NR011591:
PI Meghani, S.H.). The goal of the parent study was to explain racial and ethnic
disparities in cancer pain outcomes, specifically to elicit trade-offs that patients with
cancer pain employ in making cancer pain treatment decisions (using Choice-based
Conjoint analysis) and their actual adherence to scheduled analgesic treatment using
electronic monitoring with the Medication Event Monitoring System (MEMS®)
(Meghani et al., 2013; Meghani et al., 2015). The parent study used a prospective
observational design employing repeated measures at baseline (T1) and 3-month followup (T2). Patients were recruited from two outpatient medical oncology clinics of the
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University of Pennsylvania Health System in Philadelphia between December 2009 and
August 2011. The Institutional Review Board (IRB) of the University of Pennsylvania
approved the parent study and all participants provided written informed consent.
The current study was deemed exempt by the University of Pennsylvania
Institutional Review Board (IRB) as all protected health information was removed from
the dataset prior to study commencement and, therefore, it did not meet the definition of
human subjects research. Consistent with the parent study, the criteria specified inclusion
of patients 18 years of age or older who self-identified as African-American or White,
reported a diagnosis of multiple myeloma or solid tumors, endorsed cancer pain, and had
been prescribed at least one around-the-clock (ATC) oral analgesic. Patients using
transdermal opioid delivery systems, such as fentanyl, were not included in the parent
study sample due to MEMS® vial limitations. This current sample includes 207 selfidentified African-American and White patients (participant recruitment flow chart from
the parent study was previously published (Meghani et al., 2015); a 14% attrition rate was
noted between T1 (N=241) and T2 (N=207) with no statistically significant attrition
identified by participants’ health status or race) (Meghani et al., 2015).
Study Measures
Electronically-Monitored Analgesic Adherence using MEMS®
The MEMS® (MVW Switzerland Ltd., Sion, Switzerland) was employed to
measure objective analgesic adherence. MEMS® is a medication bottle cap that uses a
microprocessor to record in real time the event and time of a bottle opening. “Dose
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adherence” was the primary measure of adherence to ATC analgesics, defined as the
percentage of the total number of prescribed doses that were taken by a patient. For
instance, if a patient took 80 of 100 prescribed doses during the period of the study, “dose
adherence” would be 80%. The procedures for calculating dose adherence were
previously described in the parent study (Meghani et al., 2015). Investigators in the
parent study performed sensitivity analysis to account for the observer effect (e.g.,
modified analgesic taking behavior due to awareness of being observed) and compared
MEMS® dose adherence from the total number of study days to MEMS® dose
adherence if the first 30 days of observation were removed (Meghani et al., 2015).
Significant Spearman correlations for all patients in the sample (P < .001) suggested
strong internal consistency between total dose adherence scores for the study duration
and the total dose adherence scores minus the first 30 days of observations. Based on
these findings, (Meghani et al., 2015) the MEMS® dose adherence scores measuring all
monitored days in the study was selected for use in the final analysis.
Index Analgesic
Around-the-clock analgesics (index medications) were self-reported by patients
during the T1 baseline interview and confirmed through a review of electronic medical
records. Index analgesics were classified per the WHO’s (1986, 1996) analgesic ladder.
Categories include step 1 (nonopioids, e.g., nonsteroidal anti-inflammatories such as
ibuprofen or acetaminophen), step 2 (weak opioids, e.g., codeine, tramadol), and step 3
(strong opioids, e.g., methadone, oxycodone).
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Analgesic Beliefs for Cancer Pain
Maximum difference (MaxDiff) scaling was used to derive patient clusters based
on beliefs about analgesic treatment for cancer pain. Cluster membership was originally
identified using MaxDiff statistical techniques on JMP Pro 14 software as previously
described (Rosa et al., 2019). MaxDiff is a trade-off methodology rooted in Random
Utility Theory (Thurstone, 1927). It permits researchers to elicit increased choice
discrimination through forced trade-offs between items and prevents scale use bias by
requiring subjects to make clear choices rather than merely rating preference strengths as
used in other ranking or discrete choice methods (Louviere, Flynn, & Carson, 2010;
Louviere, Flynn, & Marley, 2015; Marley & Flynn, 2015; Sawtooth Software, 2019).
MaxDiff data were then subjected to a k means cluster analysis. Two unique clusters
were identified: cluster 1 (n=53) and cluster 2 (n=154), which correlated with distinct
analgesic treatment preferences. Since both clusters shared the same top ranked analgesic
belief, cluster 1 was named the “Side effects” cluster and cluster 2 the “Need it later”
cluster based on the second highest ranked preference of each group. Additional
information on the rationale for the two-cluster model is provided in a previous
publication (Rosa et al., 2019).
Self-Reported Barriers to Analgesic Use
The Barriers Questionnaire-II (BQ-II) (Ward et al., 1993) is a 27-item instrument
used at baseline (T1) to assess patient beliefs and concerns about cancer pain
management. Eight domains related to pain management concerns comprise the BQ-II: 1)
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fear of addiction; 2) fear of tolerance; 3) fear of side-effects; 4) fatalism about cancer
pain; 5) desire to be a good patient; 6) fear of distracting healthcare providers from
treating cancer; 7) fear of immune system impairment through analgesic use; and 8)
concern about analgesic use masking a patient’s ability to monitory the physiological
symptoms of his or her illness. The BQ-II demonstrates strong internal consistency at .89
(Ward et al., 1993) and measured .86 in this study.
Analgesic Side Effects
The Medication Side-Effects Checklist (MSEC) (Ward, Carlson-Dakes, Hughes,
Kwekkeboom, & Donovan, 1998) was used to capture side effects of analgesics at
baseline (T1). The MSEC identifies the presence, type, and severity of eight analgesic
side effects during the prior week (0-10 scale from no severity to extreme severity). Side
effects include constipation, drowsiness, nausea, vomiting, confusion, dry mouth, upset
stomach, and itching. The MSEC has excellent internal consistency reliability with
Cronbach α of .81 (Ward et al., 1998) and was .79 in this study.
Pain Severity and Pain Impact
Baseline measurement of both pain severity and pain impact were elicited at
baseline with the Brief Pain Inventory (BPI) (Cleeland & Ryan, 1994). The BPI measures
worst, least, and average pain scores over the week prior to assessment, as well as current
pain level (0-10 scale from no pain to pain as bad as you can imagine). The BPI has been
well-documented in research with cancer patients and demonstrates internal consistency
reliability using Cronbach α ranging from .77 to .91 (Anderson et al., 2000; Cleeland et
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al., 1994; Cleeland & Ryan, 1994; Meghani & Keane, 2007; Meghani et al., 2015; Rhee
et al., 2012; Yeager et al., 2019). In this study, the reliability coefficient was .90.
Pain Management Index
The Pain Management Index (PMI) was calculated for each patient according to
the WHO (1986, 1996, 2018) guidelines for cancer pain treatment. The PMI is reflective
of the relationship between the most potent analgesic prescribed and the patient’s selfreported pain level. The PMI is calculated by taking the most potent prescribed analgesic
and subtracting the patient’s self-reported pain level (classified using the Brief Pain
Inventory as mild, moderate, or severe). Insufficient analgesic prescription strength
relative to a patient’s self-reported pain level is typically demonstrated by a negative PMI
score.
Social Support Questionnaire
A six-item abbreviated version of the 27-item Social Support Questionnaire
(Sarason, Levine, Basham, & Sarason, 1983) was used to identify patients’ level of social
support and satisfaction with perceived support. Patients first identify the individuals in
their life who provide social support and then rate the level of satisfaction level they
experience with the support.
Demographic and Illness-Related Variables
Demographic data were self-reported and included age, gender, self-identified
race, marital status, education level, income, and health insurance type. A number of
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variables related to illness were gathered through medical chart review including cancer
type and stage, time since cancer diagnosis, past history of depression or substance abuse,
and comorbidities used to calculate a Charlson comorbidity score (Charlson, Pompei,
Ales, & MacKenzie, 1987).
Statistical Analysis
All analyses for the current study were performed using the Stata/IC 15 platform.
Descriptive statistics were generated for relevant sociodemographic and clinical
variables. Means and standard deviations are provided for continuous variables and
frequencies and percentages for categorical variables.
General linear modeling was the primary statistical method used to achieve the
study aim. Prior to building the regression model, bivariate analyses between predictor
variables and the outcome adherence variable were assessed. Relevant sociodemographic
and clinical variables significant at the bivariate level (p < .20) at T1 were considered as
potential predictors of MEMS® dose adherence at T2. Two models were then
constructed.
For model 1, variables that met the p < .20 criteria, in addition to theoretically
salient variables (e.g., history of substance abuse and presence of depression), were used
to construct a preliminary prediction model employing a backward elimination method.
The backwards elimination method is useful in evaluating the value of each potential
predictor when studying a phenomenon that may be influenced by a number of
confounders (Cohen & Cohen, 1983). After starting with all individual potential
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predictors in the preliminary model, we then subsequently removed any variable that
improved the model most significantly by its deletion. This elimination process included
theoretical variables. We repeated this process until no additional model improvement
was possible and all predictors were significant at the α = .05 level.
In model 2, the same theoretically salient variables used in the first model were
included. The clusters variable was then entered as a dichotomous categorical variable
with cluster 1 and cluster 2 as levels to evaluate the impact of analgesic treatment beliefs
on analgesic adherence by observing any change in the R-squared value. The clusters
variable was the primary variable of interest and, therefore, was retained in the backward
elimination process, regardless of statistical significance. This is consistent with the
statistical convention to maintain insignificant findings in a final model when the
explanatory variable is of primary interest or there is a specific hypothesis about a given
variable (Grace-Martin, 2020; Heinze & Dunkler, 2017).
Variance inflation factors suggested low levels of multicollinearity among
predictors in both models one and two (1.49 and 1.43 respectively) (Chatterjee & Yilmaz,
1992). Using studentized residuals during residual analysis, no observations fell beyond
the criteria of concern (x > 3, x < -3). The outcome variable was assessed using
histograms and Shapiro-Wilk test (0.87), neither of which showed concerns with
violations of normality assumptions. In addition, MEMS® dose adherence was subjected
to a sensitivity analysis to remove two observations significantly greater than 100%
adherence, which did not change the Shapiro-Wilk value.
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Results
Subjects (N=207) had a mean age of 53.8 years (SD=11.1), less than half
identified as African-American (41.5%), and most were female (56.5%). The majority
rated their general health as “good” (30.4%) or ”fair” (37.2%); less than 5% of the
sample rated their general health as “excellent” at baseline. Most patients denied a history
of substance abuse (83.1%) or current presence of depression (58%). Table 1 shows
subjects by demographic and illness variables for the entire sample and by cluster; no
significant differences between clusters were identified. Table 2 shows the belief clusters
identified in our prior study (Rosa et al., 2019).
Examining the sample by analgesic and pain management variables (Table 3)
shows that patients used a total of roughly 2.1 analgesics to treat their pain, with the vast
majority (80.2%) prescribed a strong opioid (WHO step 3). Their average least to worst
pain scores over the previous week ranged from 3.4 to 6.9 out of 10 respectively. Clusters
1 and 2 differed significantly in how they rated severity of side effects (p=0.043). There
were no statistically relevant differences between clusters in terms of other variables,
such as pain management index, pain interference, or the number of self-identified
barriers to analgesic use.
MEMS Analgesic Adherence
The clusters variable based on analgesic beliefs was not found to be statistically
significant at the bivariate level (p=0.709) but was included in all modeling computation
as the primary variable of interest. A number of relevant sociodemographic and clinical
132

variables met inclusion criteria for linear modeling (p < .20) (Table 4). Both average and
worst pain scores were tested for potential inclusion; the average pain score (p=0.004)
was selected due to a higher level of significance.
The first model showed that race, side effects, most potent analgesia prescribed,
pain relief with analgesics, and the duration of disease were all significant at the α < .05
level (Table 5). This analysis was initially generated without the cluster variable to
evaluate the relationship between other salient correlates and the MEMS variable in the
absence of cluster influence. Variables such as average pain score, history of substance
abuse, presence of depression, income, age, pain management index, and insurance type
were excluded throughout the elimination process. Approximately 21% of objective
analgesic adherence variance using MEMS was explained by the final model (r2 = 0.207).
The clusters variable was entered to Model 2 and, following the backward
elimination method, the same variables were identified as statistically significant (Table
6). Although the clusters variable was nonsignificant (p = 0.545), it remained in the
model as the primary variable of interest. Similar to the first model, these predictors
accounted for 21% of variance observed in the analgesic adherence variable (r2 = 0.208).
Discussion
We sought to determine if unique clusters based on patients analgesic treatment
beliefs predicted analgesic adherence behaviors objectively monitored using electronic
monitoring. We found that analgesic belief clusters were not statistically associated with
adherence in this adjusted analysis. However, other clinically relevant factors such as
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race, side effects, most potent analgesia prescribed, pain relief with analgesics, and the
duration of disease significantly predicted objective adherence to analgesics for cancer
pain. The findings raise important questions about the role of patient beliefs,
sociodemographic background, and clinical history in relation to adherence behaviors in
the setting of cancer pain.
While analgesic treatment beliefs, preferences, and concerns of patients and
families have been previously associated with analgesic use (Liang et al., 2013; Meghani
& Knafl, 2017; Meghani et al., 2015; Rhee et al., 2012; Simone et al., 2012), our findings
in this study show that beliefs ultimately do not explain patients’ objective analgesic
taking behaviors. For example, we found that in an adjusted analysis accounting for other
confounders, it is the experiential variables (e.g., race, side effects, most potent analgesia
prescribed, pain relief with analgesics, duration of disease) that matter most in predicting
adherence. These experiential variables have all been substantiated by extant literature as
having an impact on adherence behaviors (Manzano et al., 2014; Meghani et al., 2013;
Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 2015). These covariates
are clinically relevant and appear to be interrelated. For instance, stronger opioids may
lead to improved pain relief but may also exacerbate the severity of side effects.
Additionally, stronger opioids (e.g. WHO step 3) may also relate to more advanced
cancer diagnosis and increased adherence (Meghani et al., 2015; Oldenmenger, Sillevis
Smitt, de Raaf, & van der Rijt, 2017).
Race was the most significant among the covariates within the model, which
supports previous research findings. Studies exploring race related to analgesic adherence
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have demonstrated that African-American and White patients differ on the beliefs and
concerns most important to them. For instance, past analysis of this current sample shows
that African-Americans are most concerned about severity of side-effects, which is
positively correlated with increased nonadherence behaviors in this population (Meghani
et al., 2013; Meghani & Knafl, 2017; Meghani et al., 2015). White patients in the same
sample tended to make trade-offs based on the amount of pain relief afforded by
analgesic treatment. African-Americans in previous findings were less likely to be
prescribed long-acting WHO step 3 opioids than Whites (Meghani & Knafl, 2017).
Importantly, severity of pain was not included in either model 1 or 2 based on our
analytical exclusion criteria but remains clinically significant. More potent analgesia may
serve as a proxy for pain severity. In addition, disease duration likely serves as an indirect
proxy for pain severity as it may imply more serious pain symptoms requiring higher
potency analgesics. Of note, although theoretically salient, history of substance abuse
also was not a statistically significant variable in the final regression models. This may be
due to the fact that the vast majority of patients in the sample did not endorse a history of
prior substance abuse.
There are several limitations of this study. First, the analgesic belief clusters used
as the primary variable of interest are not exhaustive of all potential patient beliefs.
However, we used a well-substantiated tool for eliciting pain management and analgesic
concerns in the cancer pain literature. Future research may aim to elicit additional
relevant beliefs as they relate to analgesic use for cancer pain or new concerns garnering
salience in the current national context. Second, clusters based on analgesic beliefs were
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not statistically significant. Nonetheless our research supports further exploration of the
extent to which patient beliefs versus other clinical and sociodemographic variables
interact with these beliefs to impact cancer pain outcomes. Third, while a two-cluster
model was previously identified (Rosa et al., 2019), there are likely multiple groups of
patients that prioritize their beliefs differently. We anticipate the findings of this current
study are merely a starting point for identifying how variant patient priorities inform
analgesic adherence in patient populations. Fourth, while the age of the data is a concern,
the parent study collected data at the peak of the first wave of opioid epidemic. Thus, we
expect that the unique longitudinal dataset focusing on patients’ analgesic taking in the
context of opioid crisis has relevance in the current context. Last, while these findings
support previous research findings about predictors of adherence, we cannot generalize
beyond this sample.
Implications for Nursing
Nurses should observe for changing trends in opioid prescribing practices as they
relate to analgesic adherence behaviors. While certain guidelines specific for cancer pain
management continue to recommend opioids based on patients’ subjective pain report
and a combination of short- and long-acting opioids for optimal pain control (NCCN,
2019; WHO, 2018), the broader national conversation on opioid prescribing is turning
toward more modest analgesic treatment focused on short-acting opioid use (Dowell et
al., 2016). Our findings, in conjunction with the national opioid epidemic discourse,
suggest a needed re-evaluation of interventions geared toward improving adherence for
cancer pain. As suggested by this sample and a number of other studies (Meghani &
136

Bruner, 2013; Meghani et al., 2014; Oldenmenger et al., 2017; Rhee et al., 2012), there
are clearly subsets of patients that continue to require around-the-clock analgesic
prescription to effectively manage pain. Of concern, previous data highlight that patients
are not using analgesics for cancer pain on a scheduled basis. For example, previous
findings related to this current sample showed only 69% of patients (n=207) were
adherent to WHO step 3 short-acting opioids and roughly 74% were adherent to longacting opioids (Meghani & Knafl, 2017). Although there have been substantial efforts to
tailor education for patients to address analgesic beliefs and barriers, systematic reviews
show that these interventions neither improve analgesic adherence nor associated pain
outcomes for cancer pain (Bennett, Bagnall, & Jose Closs, 2009; Oldenmenger et al.,
2018; Oldenmenger, Sillevis Smitt, van Dooren, Stoter, & van der Rijt, 2009). The
evidence suggests that continued focus on evaluating key clinical variables, such as
analgesic side-effects and pain report, as well as other sociodemographic and economic
factors like race, income, and health literacy may be central to improved outcomes
associated with cancer pain (Meghani & Bruner, 2013; S.H. Meghani et al., 2013;
Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 2015).
Conclusion
This study shows that patient clusters based on analgesic treatment beliefs do not
impact adherence behaviors significantly. However, we found clinical variables that
speak to the experience of cancer pain and pain treatment are most relevant to analgesic
adherence. Our findings affirm extant literature and support ongoing evaluation to
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address, through clinical interventions, the key experiential variables that influence pain
outcomes for patients with cancer .

138

References
Anderson, K. O., Mendoza, T. R., Valero, V., Richman, S. P., Russell, C., Hurley, J., . . .
Cleeland, C. S. (2000). Minority cancer patients and their providers: pain
management attitudes and practice. Cancer, 88(8), 1929-1938.
Bennett, M. I., Bagnall, A. M., & Jose Closs, S. (2009). How effective are patient-based
educational interventions in the management of cancer pain? Systematic review
and meta-analysis. Pain, 143(3), 192-199. doi:10.1016/j.pain.2009.01.016
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of
classifying prognostic comorbidity in longitudinal studies: development and
validation. Journal of Chronic Diseases, 40, 373-383. doi:10.1016/00219681(87)90171-8
Chatterjee, S., & Yilmaz, Y. (1992). A review of regression diagnostics for behavioral
research. Applied Psychological Measurement, 16(3), 209-227. doi:
10.1177/014662169201600301.
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., Stewart, J. A.,
& Pandya, K. J. (1994). Pain and its treatment in outpatients with metastatic
cancer. New England Journal of Medicine, 330, 592-596.
doi:10.1056/NEJM199403033300902
Cleeland, C. S., & Ryan, K. M. (1994). Pain assessment: global use of the Brief Pain
Inventory. Annals, Academy of Medicine, Singapore, 23(2), 129-138.
Cohen, J., & Cohen, P. (1983). Applied multiple regression / correlation analysis for the
behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
139

Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids
for chronic pain--United States, 2016. JAMA, 315(15), 1624-1645.
doi:10.1001/jama.2016.1464
Dunkler, D., Plischke, M., Leffondre, K., & Heinze, G. (2014). Augmented backward
elimination: A pragmatic and purposeful way to develop statistical models. PLoS
One, 9(11), e113677. doi:10.1371/journal.pone.0113677
Grace-Martin, K. (2020). When to leave insignificant effects in a model. Retrieved from
https://www.theanalysisfactor.com/insignificant-effects-in-model/
Heinze, G., & Dunkler, D. (2017). Five myths about variable selection. Transplant
International, 30, 6-10. doi:10.1111/tri.12895
Hetkamp, M., Bender, J., Rheindorf, N., Kowalski, A., Lindner, M., Knispel, S., . . .
Teufel, M. (2019). A systematic review of the effect of neurofeedback in cancer
patients. Integrative Cancer Therapies, 18, 1534735419832361.
doi:10.1177/1534735419832361
Jacobsen, R., Samsanaviciene, J., Liubarskiene, Z., Sjogren, P., Moldrup, C., Christrup,
L., . . . Hansen, O. B. (2014). Barriers to cancer pain management in Danish and
Lithuanian patients treated in pain and palliative care units. Pain Management
Nursing, 15(1), 51-58. doi:10.1016/j.pmn.2012.06.002
Kim, K. S., Loring, S., & Kwekkeboom, K. (2018). Use of art-making intervention for
pain and quality of life among cancer patients: A systematic review. Journal of
Holistic Nursing, 36(4), 341-353. doi:10.1177/0898010117726633

140

Kim, T. H., Kang, J. W., & Lee, M. S. (2018). Current evidence of acupuncture for
symptoms related to breast cancer survivors: A PRISMA-compliant systematic
review of clinical studies in Korea. Medicine (Baltimore), 97(32), e11793.
doi:10.1097/md.0000000000011793
Liang, S. Y., Tung, H. H., Wu, S. F., Tsay, S. L., Wang, T. J., Chen, K. P., & Lu, Y. Y.
(2013). Concerns about pain and prescribed opioids in Taiwanese oncology
outpatients. Pain Management Nursing, 14(4), 336-342.
doi:10.1016/j.pmn.2011.08.004
Louviere, J. J., Flynn, T. N., & Carson, R. T. (2010). Discrete choice experiments are not
conjoint analysis. Journal of Choice Modelling, 3(3), 57-72. doi:10.1016/s17555345(13)70014-9
Louviere, J. J., Flynn, T. N., & Marley, A. A. J. (2015). Best-worst scaling: Theory,
methods and applications. Cambridge, United Kingdom: Cambridge University
Press.
Manzano, A., Ziegler, L., & Bennett, M. (2014). Exploring interference from analgesia in
patients with cancer pain: a longitudinal qualitative study. Journal of Clinical
Nursing, 23(13-14), 1877-1888. doi:10.1111/jocn.12447
Marley, A. A. J., & Flynn, T. N. (2015). Best worst scaling: Theory and practice. In J.D.
Wright (Ed.), International Encyclopedia of the Social & Behavioral Sciences (2nd
ed.; pp. 548-552). Elsevier, Ltd.

141

Meghani, S. H., & Bruner, D. W. (2013). A pilot study to identify correlates of
intentional versus unintentional nonadherence to analgesic treatment for cancer
pain. Pain Management Nursing, 14(2), e22-30. doi:10.1016/j.pmn.2011.03.003
Meghani, S. H., Chittams, J., Hanlon, A. L., & Curry, J. (2013). Measuring preferences
for analgesic treatment for cancer pain: How do African-Americans and Whites
perform on choice-based conjoint (CBC) analysis experiments? BMC Medical
Informatics and Decision Making, 13, 118. doi:10.1186/1472-6947-13-118
Meghani, S. H., Kang, Y., Chittams, J., McMenamin, E., Mao, J. J., & Fudin, J. (2014).
African Americans with cancer pain are more likely to receive an analgesic with
toxic metabolite despite clinical risks: a mediation analysis study. Journal of
Clinical Oncology, 32(25), 2773-2779. doi:10.1200/jco.2013.54.7992
Meghani, S. H., & Keane, A. (2007). Preference for analgesic treatment for cancer pain
among African Americans. Journal of Pain and Symptom Management, 34(2),
136-147. doi:10.1016/j.jpainsymman.2006.10.019
Meghani, S. H., & Knafl, G. J. (2016). Patterns of analgesic adherence predict health care
utilization among outpatients with cancer pain. Patient Preference and
Adherence, 10, 81-98. doi:10.2147/PPA.S93726Patterns10.2147/PPA.
S93726Patient
Meghani, S. H., & Knafl, G. J. (2017). Salient concerns in using analgesia for cancer pain
among outpatients: A cluster analysis study. World Journal of Clinical Oncology,
8(1), 75-85. doi:10.5306/wjco.v8.i1.75

142

Meghani, S. H., Thompson, A. M., Chittams, J., Bruner, D. W., & Riegel, B. (2015).
Adherence to analgesics for cancer pain: A comparative study of African
Americans and Whites using an electronic monitoring device. Journal of Pain,
16(9), 825-835. doi:10.1016/j.jpain.2015.05.009
Meghani, S. H., & Vapiwala, N. (2018). Bridging the critical divide in pain management
guidelines from the CDC, NCCN, and ASCO for cancer survivors. JAMA
Oncology, 4(10), 1323-1324. doi:10.1001/jamaoncol.2018.1574
Miaskowski, C., Dodd, M. J., West, C., Paul, S. M., Tripathy, D., Koo, P., &
Schumacher, K. (2001). Lack of adherence with the analgesic regimen: a
significant barrier to effective cancer pain management. Journal of Clinical
Oncology, 19(23), 4275-4279. doi:10.1200/jco.2001.19.23.4275
National Academies of Sciences. (2017). Pain management and the opioid epidemic:
Balancing societal and individual benefits and risks of prescription opioid use.
Washington, D.C.: National Academies Press.
National Academies of Sciences. (2018). National Academy of Medicine action
collaborative on countering the US opioid epidemic. Retrieved from
https://nam.edu/programs/action-collaborative-on-countering-the-u-s-opioidepidemic/
National Academy of Medicine. (2017). First, do no harm: Marshaling clinician
leadership to counter the opioid epidemic. Washington, D.C.: National
Academies of Sciences.

143

National Comprehensive Cancer Network. (2019). NCCN clinical practice guidelines in
oncology: Adult cancer pain V1.2019-January 25, 2019. Retrieved from
https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf
Oldenmenger, W. H., Geerling, J. I., Mostovaya, I., Vissers, K. C. P., de Graeff, A.,
Reyners, A. K. L., & van der Linden, Y. M. (2018). A systematic review of the
effectiveness of patient-based educational interventions to improve cancer-related
pain. Cancer Treatment Reviews, 63, 96-103. doi:10.1016/j.ctrv.2017.12.005
Oldenmenger, W. H., Sillevis Smitt, P. A., van Dooren, S., Stoter, G., & van der Rijt, C.
C. (2009). A systematic review on barriers hindering adequate cancer pain
management and interventions to reduce them: a critical appraisal. European
Journal of Cancer, 45(8), 1370-1380. doi:10.1016/j.ejca.2009.01.007
Oldenmenger, W. H., Sillevis Smitt, P. A. E., de Raaf, P. J., & van der Rijt, C. C. D.
(2017). Adherence to analgesics in oncology outpatients: Focus on taking
analgesics on time. Pain Practice, 17(5), 616-624. doi:10.1111/papr.12490
Paice, J. A., Portenoy, R., Lacchetti, C., Campbell, T., Cheville, A., Citron, M., . . .
Bruera, E. (2016). Management of chronic pain in survivors of adult cancers:
American Society of Clinical Oncology clinical practice guideline. Journal of
Clinical Oncology, 34(27), 3325-3345. doi:10.1200/JCO.2016.68.5206
Rhee, Y. O., Kim, E., & Kim, B. (2012). Assessment of pain and analgesic use in African
American cancer patients: factors related to adherence to analgesics. Journal of
Immigrant and Minority Health, 14(6), 1045-1051. doi:10.1007/s10903-0129582-x
144

Rosa, W. E., Chittams, J., Riegel, B., Ulrich, C. M., & Meghani, S. H. (2019). Patient
decision-making trade-offs related to analgesic use for cancer pain: A MaxDiff
analysis study. Pain Management Nursing. Epub ahead of print.
doi:10.1016/j.pmn.2019.07.013
Sarason, I. G., Levine, H. M., Basham, R. B., & Sarason, B. R. (1983). Assessing social
support: the Social Support Questionnaire. Journal of Personality and Social
Psychology, 44(1), 127-139.
Sawtooth Software. (2019). MaxDiff. Retrieved from https://www.sawtoothsoftware.
com/products/maxdiff-software/93-support/sales-support/238-maxdiff-method
Shi, Q., Smith, T. G., Michonski, J. D., Stein, K. D., Kaw, C., & Cleeland, C. S. (2011).
Symptom burden in cancer survivors 1 year after diagnosis: A report from the
American Cancer Society’s studies of cancer survivors. Cancer, 117(12), 27792790. doi:10.1002/cncr.26146
Shin, E. S., Seo, K. H., Lee, S. H., Jang, J. E., Jung, Y. M., Kim, M. J., & Yeon, J. Y.
(2016). Massage with or without aromatherapy for symptom relief in people with
cancer. Cochrane Database of Systematic Reviews, (6), Cd009873.
doi:10.1002/14651858.CD009873.pub3
Simone, C. B., 2nd, Vapiwala, N., Hampshire, M. K., & Metz, J. M. (2012). Cancer
patient attitudes toward analgesic usage and pain intervention. Clinical Journal of
Pain, 28(2), 157-162. doi:10.1097/AJP.0b013e318223be30

145

Stout, E., Sexton, P., & Meghani, S. H. (2017). Racial differences in adherence to
prescribed analgesia in cancer patients: An integrated review of quantitative
research. Journal of Clinical Outcomes Management, 24(1), 39-48.
Thurstone, L. (1927). A law of comparative judgment. Psychological Review, 34, 278286. doi:10.1037/h0070288
Torresan, M. M., Garrino, L., Borraccino, A., Macchi, G., De Luca, A., & Dimonte, V.
(2015). Adherence to treatment in patient with severe cancer pain: A qualitative
enquiry through illness narratives. European Journal of Oncology Nursing, 19(4),
397-404. doi:10.1016/j.ejon.2015.01.001
Valeberg, B. T., Miaskowski, C., Paul, S. M., & Rustoen, T. (2016). Comparison of
oncology patients' and their family caregivers' attitudes and concerns toward pain
and pain management. Cancer Nursing, 39(4), 328-334.
doi:10.1097/ncc.0000000000000319
van den Beuken-van Everdingen, M. H., Hochstenbach, L. M., Joosten, E. A., TjanHeijnen, V. C., & Janssen, D. J. (2016). Update on prevalence of pain in patients
with cancer: systematic review and meta-analysis. Journal of Pain and Symptom
Management, 51(6), 1070-1090 e1079. doi:10.1016/j.jpainsymman.2015.12.340
Ward, S. E., Carlson-Dakes, K., Hughes, S. H., Kwekkeboom, K. L., & Donovan, H. S.
(1998). The impact on quality of life of patient-related barriers to pain
management. Research in Nursing and Health, 21, 405-413.

146

Ward, S. E., Goldberg, N., Miller-McCauley, V., Mueller, C., Nolan, A., Pawlik-Plank,
D., . . . Weissman, D. E. (1993). Patient-related barriers to management of cancer
pain. Pain, 52(3), 319-324.
Wayne, P. M., Lee, M. S., Novakowski, J., Osypiuk, K., Ligibel, J., Carlson, L. E., &
Song, R. (2018). Tai Chi and Qigong for cancer-related symptoms and quality of
life: a systematic review and meta-analysis. Journal of Cancer Survivors, 12(2),
256-267. doi:10.1007/s11764-017-0665-5
World Health Organization. (1986). Cancer pain relief. Geneva, Switzerland: WHO.
World Health Organization. (1996). Cancer pain relief and palliative care. Geneva,
Switzerland: WHO.
World Health Organization. (2018). WHO Guidelines for pharmacological and
radiotherapeutic management of cancer pain in adults and adolescents. Geneva,
Switzerland: World Health Organization.
Yeager, K. A., Williams, B., Bai, J., Cooper, H. L. F., Quest, T., Meghani, S. H., &
Bruner, D. W. (2019). Factors related to adherence to opioids in black patients
with cancer pain. Journal of Pain and Symptom Management, 57(1), 28-36.
doi:10.1016/j.jpainsymman.2018.10.491

147

Table 1. Demographic and Illness Variables for Sample and by Analgesic Treatment
Belief Clusters.
Total
(N=207)

Side Effects
Cluster
(n=53)

Need it
Later
Cluster
(n=154)

P-value*

Age, y, mean (SD)

53.8 (11.1)

54.2 (12.5)

53.7 (10.7)

0.798

Time since cancer diagnosis, mo, mean
(SD)

36.7 (35.5)

30.5 (29.4)

38.9 (37.2)

0.138

Charlson Comorbidity Index, mean
(SD)

4.3 (2.6)

4.4 (2.3)

4.3 (2.8)

0.725

Health literacy, mean (SD)

13.1 (2.6)

13.3 (2.7)

13.0 (2.6)

0.413

Social support, mean (SD)

3.7 (2.1)

4.1 (2.3)

3.6 (2.0)

0.102

Physical health not good, within past
30 days, mean (SD)

14.7 (10.7)

15.7 (11.3)

14.4 (10.5)

0.439

Mental health not good, within past 30
days, mean (SD)

9.5 (10.7)

8.3 (10.1)

9.9 (10.9)

0.333

Variable

0.992

General health
Excellent

9 (4.3)

2 (3.8)

7 (4.5)

Very good

23 (11.1)

6 (11.3)

17 (11.0)

Good

63 (30.4)

17 (32.1)

46 (29.9)

Fair

77 (37.2)

20 (37.7)

57 (37.0)

Poor

35 (16.9)

8 (15.1)

27 (17.5)

Gender

0.512

Male

90 (43.5)

21 (39.6)

69 (44.8)

Female

117 (56.5)

32 (60.4)

85 (55.2)

Race
African-American

0.751
86 (41.5)
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23 (43.4)

63 (40.9)

White

121 (58.5)

30 (56.6)

91 (59.1)

Marital status

0.397

Married

110 (53)

25 (47.2)

85 (55.2)

Separated/divorced/widowed

56 (27)

19 (35.8)

37 (24.0)

Never married

41 (20)

9 (17.0)

32 (20.8)

Education

0.922

Elementary

3 (1.5)

1 (1.9)

2 (1.3)

High School

70 (33.8)

16 (30.2)

54 (35.1)

College/trade school

101 (48.8)

27 (50.9)

74 (48.1)

More than college

33 (15.9)

9 (17.0)

24 (15.6)
0.934

Job status
Full-time outside home

43 (20.8)

11 (20.8)

32 (20.8)

Part-time outside home

12 (5.8)

4 (7.5)

8 (5.2)

Full-time at home

4 (1.9)

1 (1.9)

3 (1.9)

Part-time at home

4 (1.8)

0 (0)

4 (2.6)

Retired

44 (21.3)

11 (20.8)

33 (21.4)

Unemployed

25 (12.1)

6 (11.3)

19 (12.3)

Other

75 (36.2)

20 (37.7)

55 (35.7)

Income

0.861

< 30,000

73 (35.3)

21 (39.6)

52 (33.8)

30,000-50,000

36 (17.4)

9 (17.0)

27 (17.5)

50,000-70,000

37 (17.9)

7 (13.2)

30 (19.5)

70,000-90,000

24 (11.6)

6 (11.3)

18 (11.7)

>90,000

37 (17.9)

10 (18.9)

27 (17.5)
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Insurance type

0.731

Private

107 (51.9)

25 (47.2)

82 (53.6)

Medicare

41 (19.9)

13 (24.5)

28 (18.3)

Medicaid

27 (13.1)

6 (11.3)

21 (13.7)

Multiple

25 (12.1)

1 (1.9)

5 (3.3)

6 (2.9)

8 (15.1)

17 (11.1)

Other

0.541

Cancer type
Lung

32 (15.5)

9 (17.0)

23 (14.9)

Breast

38 (18.4)

12 (22.6)

Gastrointestinal

31 (15.0)

9 (17.0)

26 (16.9)
22 (14.3)

Genitourinary/reproductive

25 (12.1)

4 (7.5)

Multiple myeloma

34 (16.4)

7 (13.2)

Other solid tumors

47 (22.7)

12 (22.6)

21 (13.6)
27 (17.5)
36 (22.7)
0.721

Cancer stage
I

20 (9.7)

2 (3.8)

11 (7.1)

II

33 (15.9)

7 (13.2)

17 (11.0)

III

37 (17.9)

6 (11.3)

25 (16.2)

IV

64 (30.9)

17 (32.1)

43 (27.9)

Unknown or unsure

53 (25.6)

21 (39.6)

58 (37.7)

History of substance abuse

0.659

Yes

35 (16.9)

10 (18.9)

25 (16.2)

No

172 (83.1)

43 (81.1)

129 (83.8)

Presence of depression

0.379

Yes

87 (42.0)

25 (47.2)

62 (40.3)

No

120 (58.0)

28 (52.8)

92 (59.7)
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NOTE: Values are n (%) unless otherwise noted.
*P-values are based on t-tests for continuous variables and χ2 for categorical
variables.Clusters 1 and 2 are based on previous findings as discussed in text.
(See table 2 for additional breakdown of clusters.)
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Table 2. Analgesic Treatment Belief Clusters (Rosa et al., 2019).
Side Effects Cluster

Rank
Order

Pain meds keep you from
knowing what is going on in

Need it Later Cluster

Pain meds keep you from
1

knowing what is going on in your

your body.

body.

It is easier to deal with the pain

If you use pain medicine now, it

than the side effects that come

2

won’t work when you need it

from the pain meds.

later.

It is important to be strong by

Pain meds weaken the immune

not talking about pain.

3

Many people with cancer get
addicted to pain meds.

Many people with cancer get
4

If you use pain medicine now, it
won’t work when you need it

system.

addicted to pain meds.
Cancer pain cannot be relieved

5

with medications.

later.
If I talk about pain, people will
think I’m a complainer.

If doctors have to concentrate on
6

pain they won’t focus on treating
the cancer.

Pain meds weaken the immune
system.

It is easier to deal with the pain
7

than the side effects that come
from the pain meds.

Cancer pain cannot be relieved

It is important to be strong by not
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with medications.

8

Pain meds make you say or do
embarrassing things.

If I talk about pain, people will
9

If doctors have to concentrate on
pain they won’t focus on

talking about pain.

think I’m a complainer.
Pain meds make you say or do

10

embarrassing things.

treating the cancer.

*Beliefs were based on the Barriers-Questionnaire-II (BQ-II) domains (see methods) and
were ranked using a maximum differential scaling derived k -means cluster analysis.
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Table 3. Analgesic and Pain Management Variables.
Variable

Total
(N=207)

Side Effects
Cluster
(n=53)

Need it Later
Cluster
(n=154)

Index analgesic, n (%)

P-value*

0.534

WHO step 1

19 (9.2)

3 (5.7)

16 (10.4)

WHO step 2

22 (10.6)

5 (9.4)

17 (11.0)

WHO step 3

166 (80.2)

45 (85.0)

121 (78.6)

Pain management index (-2 - +3)

0.5 (1.0)

0.5 (0.8)

0.6 (1.0)

0.687

Worst pain (BPI, 0-10)

6.9 (2.4)

7.1 (2)

6.8 (2.4)

0.265

Least pain (BPI, 0-10)

3.4 (2.0)

3.4 (1.9)

3.4 (2.0)

0.533

Average pain (BPI, 0-10)

4.9 (2.1)

5.0 (2.0)

4.9 (2.1)

0.397

Pain interference (BPI, 0-10)

35.2 (15.9)

36.2 (15.8)

34.9 (16.0)

0.309

Severity of side effects (MSEC, 080)

25.2 (15.0)

28.8 (15.6)

24.0 (14.6)

0.043

Barriers Questionnaire (BQ-II, 0135)

66.8 (20)

63.7 (19.4)

67.8 (20.2)

0.200

Total number of analgesics
prescribed (excluding coanalgesics)

2.1 (0.8)

2.2 (1.0)

2.0 (0.7)

0.155

Total number of co-analgesics
prescribed

0.2 (0.5)

0.3 (0.6)

0.2 (0.5)

0.322

65.1 (34.5)

63.6 (33.9)

65.6 (34.9)

0.645

% overall adherence

NOTE: Values are mean (SD) unless otherwise noted.
Abbreviations: WHO, World Health Organization; BPI, Brief Pain Inventory; MSEC,
Medication Side-Effects Checklist; BQ, Barriers Questionnaire
*P-values are based on t-tests for continuous variables and χ2 for categorical variables.
Clusters 1 and 2 are based on previous findings cited earlier.
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Table 4. Bivariate Results of Predictors of MEMS® Adherence Included in Linear
Modeling.
Variable

P Value*

Clusters

0.709

Age

0.201

Race

0.000

Income

0.064

Private insurance

0.003

(missing data n=203)
Duration of disease

0.010

Side effects magnitude

0.140

Average pain (last week)

0.004

Most potent analgesic

0.002

Pain management index

0.001

Pain relief with analgesics

0.003

Presence of depression

0.329

History of substance abuse

0.260

*P-values are based on bivariate analysis of variance (ANOVA) for all variables.
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Table 5. Predictors of Objective Analgesic Adherence Excluding Clusters Variable.

Variable

F Statistic

P-Value*

Race

19.27

0.000

Side effects

4.22

0.041

Most potent analgesia

3.45

0.034

Pain relief with analgesics

7.69

0.006

Duration of disease

9.05

0.003

*P-values based on general linear modeling.
** 2

r =0.207
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Table 6. Predictors of Objective Analgesic Adherence Including Clusters Variable.

Variable

F Statistic

P-Value*

Clusters

0.37

0.545

Race

19.27

0.000

Side effects

4.22

0.041

Most potent analgesia

3.45

0.034

Pain relief with analgesics

7.69

0.006

Duration of disease

9.05

0.003

*P-values based on general linear modeling.
** 2

r =0.208
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CHAPTER 5
Summary of Integrated Findings and Discussion
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Summary of Integrated Findings and Discussion
Through literature review, conceptual and empirical analyses, and iterative
syntheses of findings, this dissertation explored patients’ analgesic treatment beliefs for
cancer pain and the association of those beliefs with objective analgesic adherence
behaviors. This timely focus is critical to better understanding how patient beliefs,
analgesic adherence measures, and cancer pain management intersect in the context of
the opioid epidemic. Importantly, the significance of this work is rooted in the high
prevalence of moderate to severe cancer pain (Shi et al., 2011; van den Beuken-van
Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, & Janssen, 2016), as well as the
policy and scientific initiatives that are impacting opioid monitoring and prescribing
practices, as well as pain relief guidelines across settings (Christie et al., 2017; National
Academies of Sciences, 2017, 2018; National Academy of Medicine, 2017; U.S.
Department of Health and Human Services, 2019).
Despite cancer pain guidelines that identify World Health Organization (WHO)
step 3 opioids (e.g., morphine, hydromorphone) as the foundation of moderate to severe
cancer pain treatment plans (National Comprehensive Cancer Network [NCCN], 2019;
Paice et al., 2016; WHO, 2018), other recommendations discourage the use of such
opioids for cancer survivors or patients not receiving palliative or end-of-life care
(Dowell, Haegerich, & Chou, 2016). Discrepancies in these guidelines have contributed
to oncology clinicians’ uncertainty about opioid prescribing and use, as well as potential
risks to patient safety given differing expert recommendations (Meghani & Vapiwala,
2018; Ranapurwala, Naumann, Austin, Dasgupta, & Marshall, 2018). The interplay of
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divergent pain management guidelines, high cancer pain burdens, and the clinical
implications of the opioid epidemic - such as pre-authorization insurance requirements
for analgesics and more conservative prescribing practices – require more research that
elucidates the factors influencing patients’ analgesic taking behaviors (Johnson et al.,
2018; Lamar, 2018; National Academies of Sciences, 2017).
There has been much described throughout the prior chapters about the prescriber
and healthcare system aspects of analgesic use. However, there continues to be an
empirical gap in understanding patients’ beliefs about analgesic treatments for cancer
pain, and especially, how those beliefs inform their objective analgesic adherence. Three
studies were conducted to achieve the overall aim. The first was a concept analysis
(chapter 2) that provided a basis for later data analyses and a lens through which to
consider study findings. Subsequently, in chapters 3 and 4, we quantitatively explored the
phenomenon of interest by analyzing the significance of patients’ cancer pain treatment
beliefs and then determining the correlation of those beliefs with their analgesic
adherence behaviors. The purpose of this chapter is to articulate overall conclusions
through a review of chapter aims and synthesis of key findings, implications for future
practice, education, research, and policy domains, and the major strengths and limitations
of the dissertation.
Review of Chapter Aims and Synthesis of Key Findings
In chapter 1, we provided an overview and background of the phenomenon of
analgesic nonadherence, particularly in the context of the opioid epidemic. Additionally,
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we made explicit the innovation of this current work and identified the relevant sample
and variables from the parent study, as well as the methods, to be used throughout the
dissertation. In this first section, the salience of additional scientific inquiry pertaining to
analgesic adherence for cancer pain was emphasized, including a substantive literature
gap and critical need to better understand the patient perspective related to analgesic use
for cancer pain.
In chapter 2 (Rosa, Riegel, Ulrich, & Meghani, 2020), a concept analysis of
analgesic nonadherence for cancer pain in a time of opioid crisis using the Walker and
Avant (2019) method was presented. The purpose was to clarify the concept of analgesic
nonadherence for cancer pain and qualify its utility in the context of the epidemic. To our
knowledge, this was the first conceptual analysis of analgesic nonadherence among this
population and was a vital step to clarifying how the concept is employed and measured
in the literature, and the impact of differing analgesic adherence behaviors on patients
and cancer pain outcomes.
Of note, we found that few studies made the link between analgesic nonadherence
and patient outcomes. For example, only one study identified inconsistent opioid
adherence for cancer pain as the strongest predictor of hospitalization (Meghani & Knafl,
2016). In addition, increased nonadherence due to patient or family hesitancy to use
analgesics as prescribed was correlated with increased pain severity and negative
consequences on physical and social function that decreased overall quality of life (Lee et
al., 2015; Manzano, Ziegler, & Bennett, 2014). In fact, the lack of empirical data
alongside the widespread implications of the opioid crisis and dissonance among pain
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management guidelines created a lack of clarity about the utility of analgesic
nonadherence as a concept in the field.
Ultimately, the concept analysis provided a rationale for the additional studies in
chapters 3 and 4. The synthesis of the literature created more questions than answers.
First, the specific elements that constituted optimal adherence behaviors related to
prescribed analgesics for cancer pain were unclear. Both a lack of evidence in
conjunction with the practice and policy changes discussed above made evident the need
for additional empirical findings that elucidated the phenomenon of analgesic
nonadherence for the cancer patient population. Second, although the national
sociopolitical dialogue has focused on how to balance social welfare with individual pain
alleviation in this time of opioid crisis (National Academies of Sciences, 2017), more
data was needed to better understand what factors influence patients’ adherence
behaviors. Third, the disagreement between opioid prescribing guidelines, as well as the
lack of empirical evidence to support those guidelines, is a barrier to understanding
analgesic nonadherence for cancer pain. For example, as argued by Meghani & Vapiwala
(2018), the Center for Disease Control (CDC) guidelines discourage the concomitant use
of extended- and immediate-release opioids (Dowell et al., 2016) while a number of
national organizations promote this multimodal approach for effective pain relief
(NCCN, 2019; Paice et al., 2016; WHO, 2018). Analgesic nonadherence in this time of
the CDC guidelines – and in the absence of high-quality empirical data to support these
guidelines - complicates clarity around prescribing, monitoring, and effectiveness.
Fourth, many studies used various surveys and instruments to measure adherence rates
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but there was a substantial gap related to the underlying patient decision-making
processes that inform analgesic taking behaviors. This gave validity to the need to further
explore the decision-making utilities employed by patients when thinking about their
analgesic medications to treat their cancer pain.
In chapter 3 (Rosa, Chittams, Riegel, Ulrich, & Meghani, 2019), we briefly
discussed how many patients with cancer pain deviate from their prescribed analgesic
regimens for a host of reasons (e.g., severity of side effects, concern about dependence or
addiction, family or caregiver hesitancy to use analgesics), including their analgesic
treatment beliefs (Manzano et al., 2014; Meghani & Bruner, 2013; Meghani, Chittams,
Hanlon, & Curry, 2013; Meghani, Thompson, Chittams, Bruner, & Riegel, 2015; Rhee,
Kim, & Kim, 2012; Schumacher et al., 2014b; Simone, Vapiwala, Hampshire, & Metz,
2012). Specifically, the aims of this study were to (1) elicit the trade-offs patients make
based on their beliefs about analgesic use; (2) rank utilities (importance scores) using a
maximum difference (MaxDiff) scaling-derived k means cluster analysis to evaluate how
beliefs differed between groups; and (3) describe clusters by comparing key
sociodemographic and clinical variables. MaxDiff - a consumer preference tool rooted in
random utility theory (Thurstone, 1927) - is underutilized in the social sciences literature
and provided us with an innovative empirical approach to understanding how groups of
patients prioritize their beliefs around analgesic treatment for cancer pain, based on a
widely used barriers to cancer pain management validated instrument (Ward et al., 1993).
A primary finding of chapter 3 was that patients’ beliefs are significant in their
choices when thinking about pain medicines. This finding aligns with extant literature
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showing an association between analgesic beliefs and analgesic adherence behaviors
(Liang et al., 2013; Meghani & Bruner, 2013; Torresan et al., 2015; Valeberg,
Miaskowski, Paul, & Rustoen, 2016). The analysis showed that trade-offs based on
particular beliefs about cancer pain management strongly effected choices about
analgesic use.
For instance, patients across the sample were about 24% more likely to make
trade-offs about analgesic medications based on the belief that “pain meds keep you from
knowing what is going on in your body”. In other words, “knowing body” was identified
as the most important belief and patients were more likely to make choices based on this
belief over other beliefs. In fact, the belief of “knowing body” may be a key aspect of
understanding primary concerns regarding analgesic taking behaviors among patients
with cancer who experience pain. Researchers have found that many patients link the
presence of pain with disease status and, therefore, the need to “know their body” is
crucial (Rau et al., 2017). Furthermore, patients who have shown intentionally
nonadherent behaviors (e.g., stop taking analgesics when they feel better or worse) agree
with the belief of “knowing body” (Meghani & Bruner, 2013). This suggests that the
desire to “know body” may often be prioritized over adherence to prescribed analgesic
regimens or the need to mitigate pain symptoms. Additional studies show that some
patients deny pain as a symptom of disease (Torresan et al., 2015) and others believe
opioids should only be used in advanced disease stages (Liang et al., 2013), supporting
the idea that analgesics may only be more readily utilized when patients have a reliable
understanding of what is happening in their bodies.
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Given the urgency surrounding the national opioid epidemic discourse, it was
somewhat surprising to see that patients across the sample in our MaxDiff study ranked
the belief that “many people with cancer get addicted to meds” as only moderately
important (ranked fourth out of ten beliefs). Taking into consideration that these data
were collected during the second wave of the opioid crisis in the United States (20092011), we originally anticipated that subjects would have given more weight to this
belief. Some previous studies do acknowledge patient concern about physiological
dependence or addiction to opioids as a decision-making factor affecting analgesic use
(Jacobsen et al., 2014; Liang et al., 2013; Simone et al., 2012). However, our findings
support previous research that addiction concerns do not ultimately explain either
objective or subjective measures of analgesic adherence in the cancer patient population
(Meghani et al., 2015; Rhee et al., 2012). If the parent study were to be replicated today,
we assume addiction concerns might generate a higher utility given the consequences of
the third wave of the epidemic that started in 2013 (CDC, 2018) related to synthetic
opioid overdose deaths. This would support other recent findings that show addiction was
the second top concern among ambulatory patients undergoing active cancer treatment
(Meghani et al., 2020). The MaxDiff trade-off findings highlight the need to better
understand how patients’ preferences and beliefs related to analgesic use may differ from
national research and policy initiatives focused on more conservative opioid prescribing
practices to mitigate addiction risk.
Following the initial MaxDiff operation, a cluster analysis identified two distinct
clusters of patients based on analgesic treatment beliefs, representing unique decision165

making utilities. A primary takeaway from this analysis shows that there is significant
variation in how clusters of patients prioritize their beliefs related to cancer pain
treatment, and this variation likely reflects differences in individual beliefs and the utility
of those beliefs when thinking about analgesic use. The only sociodemographic or
clinical variable that differed significantly by cluster was the belief that “it is easier to
deal with the pain than the side effects that come from the pain meds”. This outcome
aligns with empirical data associating an increased number of side effects and severity of
those side effects with an increase in nonadherence to analgesics (Manzano et al., 2014;
Meghani & Bruner, 2013; Meghani et al., 2014). Our findings suggest that the utility of
the “side effects” belief may be salient concern for some patients with cancer pain and
not for others. Thus, it appears that patients prioritize beliefs around analgesic use quite
differently. In fact, the cluster analysis showed significant variation between how the two
clusters prioritized analgesic treatment beliefs. This variation likely reflects individual
belief differences and the weight patients give to those beliefs regarding analgesic use
trade-offs. This outcome is consistent with researchers who found more than a quarter of
patients traded-off on analgesic decisions based on a number of differing concerns,
including the type and the severity of side effects (Meghani & Knafl, 2017).
Subjects in cluster 2 ranked the belief, “If you use pain medicine now, it won’t
work when you need it later,” as the second rated utility. Patients have previously noted
concern that if opioids are used in earlier stage disease than their analgesic effect may be
less potent later on as symptoms worsen (Liang et al., 2013). This worry about tolerance
to pain medication is likely an ongoing concern for patients with moderate to severe
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chronic cancer pain who require analgesic treatment over time. Findings show that pain
continues to be one of the top three most troubling symptoms at one-year post-diagnosis
and cancer survivors tend to report levels of pain similar to those undergoing active
treatment (Shi et al., 2011). A number of utility scores were ranked quite low among both
clusters, including, “Won’t focus on cancer,” “Be strong,” “Say embarrassing things,”
and “Complainer.” These low-ranking utilities reflect a prior study showing that for
patients with cancer pain, these beliefs are less important than “Knowing body” or “Harm
immune system” (Valeberg et al., 2016).
The analysis conducted in chapter 4 explored whether the analgesic treatment
belief clusters from the previous chapter predicted objective analgesic adherence
behaviors using an electronic medication monitoring system known as the Medication
Event Monitoring System (MEMS®; MVW Switzerland Ltd., Sion, Switzerland). A
general linear modeling was used with a backward elimination approach to identify
significant correlates of MEMS® adherence data (Cohen & Cohen, 1983). Relevant
confounders and theoretically salient variables were accounted for throughout the
analysis to determine the significance of sociodemographic (e.g., race), clinical (e.g.,
duration of disease), and pain-related (e.g., most potent analgesia prescribed and pain
relief with analgesics) explanatory factors.
Prior to conducting the chapter 4 analysis, we hypothesized that analgesic
treatment belief clusters would be predictive of objective analgesic adherence. However,
they were not statistically significant in our linear modeling results. Chapter 3 findings
suggested that analgesic treatment beliefs weigh significantly in the choices patients
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articulated regarding analgesic use and there are unique subgroups of patients based on
these analgesic beliefs. However, our chapter 4 outcomes showed that beliefs did not
predict objective adherence behaviors. In fact, in an adjusted analysis when accounting
for relevant confounders, it was ultimately experiential variables that drive their objective
analgesic use. For example, multiple predictors of adherence were noted and support
findings from prior studies, including race, side effect severity, the type of analgesia
prescribed, pain relief from analgesics, and the duration of disease (Manzano et al., 2014;
Meghani et al., 2013; Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al.,
2015). These variables explained 21% of the variance in electronically-monitored
analgesic adherence at T2.
Among these factors, race was the most significant predictor in the model and has
consistently been shown to impact adherence behaviors. Our findings reflect those of
other researchers who have shown, for example, that African-Americans are less likely to
be prescribed an extended-release WHO step 3 opioid for cancer pain management than
Whites and also have increased concern about analgesics side-effect severity, correlating
with increased nonadherence behaviors (Meghani & Bruner, 2013; Meghani & Knafl,
2017; Meghani et al., 2015). The remaining covariates are clinically relevant. In Chapter
4 we give the example of how these variables relate to one another and adherence
behaviors: Stronger opioids may lead to improved pain relief but may also exacerbate the
severity of side effects. Additionally, stronger opioids (e.g. WHO step 3) may also relate
to more advanced cancer diagnosis and increased adherence (Meghani et al., 2015;
Oldenmenger, Sillevis Smitt, de Raaf, & van der Rijt, 2017).
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It is important to note the clinical relevance of pain severity in the analgesic
adherence and cancer pain research. Although pain severity was not statistically
significant in our linear models based on our analytical exclusion criteria, a number of the
variables that were predictive of adherence may serve as proxies for pain severity. For
instance, more potent analgesia and duration of disease, both of which indirectly imply
greater levels of pain and potentially disease progression. In addition, history of
substance abuse was not found to be significant in our modeling, however, a majority of
subjects in this sample did not report history of substance abuse.
A key question raised in chapter 4 by these findings is: How useful is the concept
of analgesic adherence for cancer pain amid evolving prescribing guidelines secondary to
the opioid addiction epidemic? As guidelines continue to emphasize the utilization of
immediate-release, as-needed analgesics for pain management, further research and
scholarly dialogue should address the validity of measuring adherence behaviors.
Adherence - as a measure - is only effective for tracking patient consumption of
scheduled, extended-release opioids in this clinical scenario. To this end, our overall
findings support a need to re-evaluate how we measure and understand analgesic use for
this population. The current literature suggests that patients have low to moderate
analgesic adherence rates at best and significant variability in using prescribed analgesics
(Meghani & Knafl, 2017). Furthermore, several varied patient education interventions
(e.g., booklets, video/computer programs, face-to-face instruction) improve pain
outcomes only for a small percentage of patients, likely due to their inability to
individualize approaches to alter beliefs or concerns (Bennett, Bagnall, & Jose Closs,
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2009; Oldenmenger et al., 2018; Oldenmenger, Sillevis Smitt, van Dooren, Stoter, & van
der Rijt, 2009). However, there will continue to be a subset of patients who will require
around-the-clock analgesics for the relief of moderate or severe pain where adherence
measurement would continue to remain clinically relevant (Meghani & Bruner, 2013;
Meghani et al., 2014; Oldenmenger et al., 2017; Rhee et al., 2012).
Better understanding self-management approaches of patients with cancer pain
may be integral to improving cancer pain outcomes and understanding underlying
analgesic taking behaviors. Of note, researchers have found there are potentially unsafe
self-management strategies employed by cancer pain patients that require timely
attention, such as self-tapering opioids, cutting pills, substituting extended-release opioids
for “as needed” relief, and using over-the-counter and illicit drugs to mitigate or avoid
opioids (Meghani et al., 2020). Ultimately, the findings in chapter 4 support continuing to
evaluate key structural and clinical variables, such as analgesic side-effects, pain reports,
and other sociodemographic and economic factors, such as race, is likely central to
improving cancer pain outcomes (Meghani & Bruner, 2013; Meghani et al., 2013;
Meghani et al., 2014; Meghani & Knafl, 2017; Meghani et al., 2015; Yeager et al., 2019).
Considering analgesic adherence from a broader perspective, integrating beliefs, selfmanagement practices, clinically relevant confounders, and the experiential variables we
identified as significant is likely to improve pain outcomes and provide a more in-depth
understanding of this phenomenon in the cancer pain setting.
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Implications
There are limited empirical data on long-term opioid use (e.g., more than three
months) to inform best practices, leading to conflicting opioid prescribing
recommendations among guidelines (Dowell et al., 2016; Meghani & Vapiwala, 2018;
NCCN, 2019; Paice et al., 2016; WHO, 2018). This has led to concerns about how to best
prescribe opioids and other analgesics for cancer pain (e.g., immediate- vs. extendedrelease, around-the-clock vs. as needed). One of the most relevant questions to emerge
from this work is: What is the role of opioid ‘adherence’ in the era of the CDC guidelines
(Dowell et al., 2016) and national concerns with opioid crisis?
Organizational and policy responses are underway to address some of the
challenges secondary to the rapid and, at times, misappropriated uptake of the CDC
guidelines (Dowell, Haegerich, & Chou, 2019), such as sudden discontinuation or taper
of analgesic dosing or barriers to multimodal pain care access. Continued education for
prescribers and policy makers that reflects the accuracy of the CDC prescribing
guidelines in their entirety is imperative to ensure responsible opioid dosing and planning
(Kroenke et al., 2019). When considering the findings from this dissertation amid the
opioid crisis, we must evaluate the resources and energy being used to advance the
science of analgesic adherence for cancer pain given the evolution of the concept in
keeping with many prescribing guidelines (as discussed above). Extant studies already
suggest that significant portions of patient samples demonstrate low adherence rates to
their prescribed regimens on a scheduled basis (Meghani & Bruner, 2013; Meghani &
171

Knafl, 2017; Oldenmenger, Sillevis Smitt, de Raaf, & van der Rijt, 2017). Therefore, we
must consider potential implications across clinical practice, education, research, and
policy to promote safe patient outcomes and further understanding the correlates of
prescribed analgesic taking behaviors.
Clinical Practice and Education
There are several potential clinical practice and education implications suggested
by the findings. First, clinicians might consider exploring and understanding patients’
analgesic beliefs throughout the initiation and evaluation of cancer pain treatment plans.
Although belief clusters did not correlate with adherence outcomes in our study, patient
beliefs were still significant for patients in thinking about their pain medicines according
to our MaxDiff utility analysis. Importantly, clinicians should assess for details regarding
the experiences of cancer pain and pain treatment that inform analgesic beliefs and
preferences. Clinicians who both prescribe and administer analgesics may develop plans
for eliciting and considering these experiences in relation to prescribed analgesic
treatments to better adjust for individual needs. Developing analgesic regimens in
partnership with patients amid conflicting pain management guidelines provides an
opportunity to promote patient- and family-centered care. Furthermore, a deeper
understanding of the patient perspective may improve clinician-patient relationships and
more transparent dialogue regarding the status of pain and its effective management.
Second, prescribers must gain a better understanding of what patients believe
about the strength of opioids being used. While it has been noted that nonopioids and
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weak opioids cause fewer side effects and should be optimized when possible (WHO,
1986, 1996), strong opioids continue to be the recommendation of many guidelines for
moderate to severe cancer pain (NCCN, 2019; Paice et al., 2016; WHO, 2018).
Understanding potential hesitancies to use opioids from patients and family caregivers
will likely assist in ensuring pragmatic interventions for pain relief that are acceptable to
the context of the family and caregiver dynamics.
Third, patient-based education programs for patients intended to improve painrelated outcomes have been largely unsuccessful (Oldenmenger et al., 2018). Rather than
relying solely on education approaches that are still quite heterogenous (e.g., booklets,
video/computer programs, face-to-face contact), a more dexterous investigation of
patients’ self-management strategies will aid in identifying problematic analgesic taking
behaviors and the role of these behaviors on outcomes (Meghani et al., 2019). In addition,
further attention to systemic, structural, and sociodemographic factors likely influencing
analgesic use, as noted by findings from chapter 4 above, is vital. In fact, improved focus
on mitigating side-effects and addressing sociodemographic issues of race, income, and
health literacy at the structural and systemic level may have more influence in improving
cancer pain outcomes. Considering these confounders during patients interviews and
other encounters may facilitate the identification of additional barriers, facilitators, and
factors impacting the patient experience of pain, as well as pain relief.
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Research and Policy
First, healthcare workers and advocates must continue to support efforts in
research and policy that balance societal welfare with individualized pain management
(Christie et al., 2017; National Academies of Sciences, 2017, 2018). The dissertation
findings suggest that clinicians must continue to better understand individual beliefs and
preferences related to analgesic use. At the same time, we must also be cognizant of the
impacts of the opioid epidemic on the broader population. This is both a delicate balance
and empirical imperative. In particular, the long-term risks and benefits of analgesic use
are necessary to explore to ensure an informed patient and clinician population. The high
prevalence of cancer pain carries an ethical obligation that pain and its associated
suffering be adequately managed through appropriate care planning and pain burden
interventions.
Second, additional qualitative research that provides more subjective data on
analgesic beliefs and preferences in a time of the opioid epidemic is warranted. While
there are a number of qualitative studies available that study the phenomenon of
analgesic adherence for cancer pain (Manzano et al., 2014; Schumacher et al., 2014a,
2014b), they largely rely on semi-structured interviews. One recent study utilized a
freelisting method, in addition to interviews, to investigate opioid self-management
practices for cancer pain patients (Meghani et al., 2020). Methodologies such as concept
mapping and ethnographic observation (to the extent possible) may provide additional
insights into the behaviors and contextual dynamics surrounding prescribed analgesic
taking habits. In particular, approaches that further elicit analgesic beliefs and preferences
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from different groups based on the experiences of cancer pain and analgesic treatment
options of patients, families, and prescribers may be helpful in understanding divergent
priorities among populations. Additional qualitative inquiry may also shed more light on
patient concerns not measured in this dissertation and provide further information on how
beliefs interact with systemic/structural and family dynamics to influence analgesic
taking behaviors and cancer pain outcomes - multifactorial interactions discussed only
minimally in prior literature (Schumacher et al., 2014a, 2014b).
Third, further research that explores complementary and integrative health
approaches to cancer pain management is needed (Bao et al., 2014). Such interventions
are supported by pain management guidelines (Dowell et al., 2016; NCCN, 2019).
However, at this time there is insufficient evidence to support their clinical efficacy in
managing various types of cancer pain (Hetkamp et al., 2019; Kim, Loring, &
Kwekkeboom, 2018; Kim, Kang, & Lee, 2018; Shin et al., 2016; Wayne et al., 2018). As
pain outcomes data related to complementary and integrative health services are obtained
through expanded research initiatives, policies that increase access to, and plan coverage
and affordability of these services - in conjunction with more traditional analgesic and
interventional pain relief options - will be imperative to ensure pain care equity across
patient populations (U.S. Department of Health and Human Services, 2019).
Finally, continued efforts to clarify the association between patients’ analgesic
beliefs and analgesic taking behaviors is needed to further personalize care and improve
safety and health outcomes. While the two analgesic treatment belief clusters were not
statistically associated with objective adherence behaviors in this dissertation work, there
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are likely multiple groups of patients that prioritize beliefs in different and nuanced ways,
which informs their analgesic use accordingly. Further scientific inquiry should assess for
these additional decision-making patterns. In the end, policies that ensure timely pain
management for any patient experiencing pain secondary to cancer are needed across
institutional and system-wide settings.
Strengths and Limitations
There are a number of strengths of this dissertation. First, a distinct advantage was
the use of a rare existing dataset that permitted the measurement of longitudinal and
objective analgesic and opioid adherence behaviors in the outpatient oncology setting
(Meghani et al., 2015; Meghani & Knafl, 2017). To our knowledge, this is the only
dataset that accomplishes these empirics in the United States, with the exception of a
single recent study that observed a significantly smaller sample (N=17) (Wright et al.,
2019). Second, the sample used was roughly 42% African-American, representing the
beliefs, demographics, and pain background of an historically underrepresented group.
Third, the final sample used (N=207) was from T2 and showed no disproportionate
attrition based on sociodemographic or clinical data from baseline. Last, this dissertation
is the first to employ MaxDiff analysis in this particular field, making a strong case for
future use of this approach in healthcare research, particularly in order to better
understand how patients trade-off on their decision-making processes around analgesic
use.
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A primary limitation of the empirical portions of the dissertation is the age of the
data, which was collected between 2009 and 2011. However, it is important to consider
that this time period aligned with the second wave of the opioid crisis, carrying current
implications for the ongoing sociopolitical context (CDC, 2018). Second, the sample
itself was limited to African-American and White patients, excluding the decisionmaking utilities of patients from other diverse and minority backgrounds. However, this
sample met the aims of the parent study, which focused on cancer pain disparities,
specifically between African-American and White patients. Third, while the beliefs
evaluated in the MaxDiff questionnaire were based on a well-validated cancer pain
barriers tool (Ward et al., 1993), this instrument is likely not inclusive of all potentially
influential beliefs considered when trading-off on decisions regarding analgesic use for
cancer pain. In addition, while we focused on patient beliefs, the study was not inclusive
of provider-, family-, or system-level influences associated with analgesic adherence
behaviors or how those factors may impact patients’ individual beliefs. Further research
is needed to evaluate a more holistic assessment of beliefs and their association with
analgesic adherence in the context of these broader interpersonal and structural
considerations. To date, there are limited data that explore the impact of family and
caregiver hesitancy on analgesic use as discussed above. Lastly, while our findings are
confirmatory of previous research findings in this area, we cannot generalize beyond this
sample.
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Conclusion
Cancer pain is a debilitating and highly prevalent symptom that impacts patients
and their families. Analgesics are the cornerstone of cancer pain management and, in
particular, opioids continue to be foundational for moderate to severe cancer pain
treatment according to cancer pain guidelines. The phenomenon of analgesic
nonadherence for cancer pain requires further scholarly dialogue amid this context of the
opioid crisis but also additional empirical and normative research to elicit its link to and
validity in improving cancer pain and health outcomes.
Our findings suggest that experiential variables rather than analgesic beliefs were
associated with analgesic adherence in this sample of cancer outpatients. However, the
field needs more investigation to understand exactly how patients prioritize those beliefs
in a broader sense, how they trade-off on what is most important to their sense of health
and well-being, and how the current climate of the opioid crisis, as well as the input of
family and prescribers, influence those beliefs. Importantly, our research supports
continued emphasis on systemic and structural influences to understand analgesic taking
behaviors - such as race, income, and health literacy - as well as further studies that
describe self-management practices related to prescribed analgesics and opioids. These
factors must be addressed to ensure pain management equity for all those suffering from
cancer pain.
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Early in the dissertation, we noted that it is impossible to sever the complexities
of the opioid epidemic from the phenomenon of analgesic nonadherence for cancer pain.
The opioid epidemic is, indeed, an antecedent of analgesic use for cancer pain. This
sociopolitical milieu of the evolving opioid crisis is expected to continually shape
patients’ beliefs, preferences, and values and health providers’ prescribing practices, as
well as policies that inform opioid access. Future studies should focus on these multilevel factors and complexities in meaningfully addressing the burden of cancer pain amid
the opioid crisis.
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